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ABSTRACT
Ischemic events associated with coronary heart diseases (CHD) are the leading cause of
death worldwide for both genders. They are directly associated with restricted blood flow caused
by accumulation of atherosclerotic plaque in vessel’s lumen. Percutaneous coronary intervention
(PCI), including stent deployment, is currently considered as the dominant procedure for
mechanically recovering myocardial perfusion to avoid lethal ischemic events. As vascular
prosthesis, coronary stents suffer from two major and common complications; thrombosis and
restenosis. Thrombosis is linked with insufficient migration of endothelial cells (EC) and
proliferation at site of tissue injury. Restenosis is caused by unwanted proliferation of underlying
vascular smooth muscle cells (VSMC). With drug eluting stents (DES) as a strategy to mitigate
aforementioned complications, it only results in reducing VSMC proliferation. However, it
directly causes poor endothlialization through undifferentiated inhibition of endothelial cells as
well. This can result in high risk of late thrombosis, leading to death.
Different strategies are being investigated to reach optimum duration and conditions for
endothelium healing as a critical aspect of enhancement for drug eluting stents. In this thesis, a
nanoarchitectured system is proposed as surface enhancement for drug eluting stents. Highly
oriented nanotubes were vertically grown on the surface of a biocompatible Ti-based alloys, as
potential material for self-expandable stents. The fabricated nanoarchitectured system is selfgrown from the potential stent substrate. This material is also proposed to enhance endothelial
proliferation while acting as drug reservoir to hinder VSMC proliferation.
Two morphologies were prepared to investigate the effect of structure homogeneity on
the intended application. They were characterized for morphological investigation using Fieldemission scanning electron microscope (FESEM), X-ray diffraction (XRD), Raman
spectroscopy, Energy dispersive X-ray spectroscopy (EDX) and X-ray photoelectron
spectroscopy (XPS). Nanoindentation technique was used to study the mechanical properties of
the fabricated material. Cytotoxicity and proliferation studies were done and compared for the
two fabricated nanoarchitectures versus smooth untextured samples using in-vitro cultured
endothelial cells. Finally, drug loading capacity was investigated practically and supported by
computational study of release profile using COMSOL® Multiphysics software.
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Chapter 1: Introduction and Scientific
Background

Chapter 1: Introduction and Scientific Background
1.1.

Coronary Heart Disease (CHD)

Coronary heart disease (CHD) is described as the leading cause of death worldwide for both
genders, especially in high and middle-income countries. It is responsible for 30% of deaths
annually around the world and the death of almost 700,000 patients in the United States of
America alone every year

1–3

. It has been intrinsically associated with atherosclerosis since the

beginning of the 20th century 1. Atherosclerosis is a degenerative disease that can begin as early
as adolescence or childhood. It progresses silently until adulthood, when it can be manifested
into clinical CHD that may end with death 4. Pathologically, atherosclerosis is characterized by
the formation of localized plaques within arterial walls that hinder normal blood flow 5.

As shown in Figure 1.1, atherosclerosis starts with the accumulation of fatty streaks,
cholesterol deposits and its esters in arterial intima. Later, larger lipid deposits and cellular waste
are accumulated and covered by a thick intima of connective tissue and smooth muscles,
resulting in a fibrous plaque. That fibrous plaque can either stay stable and get calcified or can
erode exposing the inner core to flowing blood, which in turn may accumulate into occlusive
thrombus 4. When atherosclerotic plaques are localized in one or more of coronary arteries –
known as coronary artery disease (CAD) – they prevent sufficient flow of oxygenated blood to
the heart muscles. This results in an ischemic state at the heart muscle causing symptomatic
events that range from angina pectoris to myocardial infarction and sudden death 6, see Figure
1.2.

2

Figure 1.1: Schematic representation of atherosclerosis timeline pathologically 7

The clear-cut cause of atherosclerosis is not well-identified up till now. However, several risk
factors were highlighted to significantly contribute in disease progression; such as hypertension,
diabetes mellitus, smoking and most importantly uncontrolled blood lipid profile 1. Further
identification of cholesterol role was revealed when high blood levels of low-density lipoprotein
(LDL) cholesterol accompanied higher rates of CHD incidence, while high blood levels of highdensity lipoprotein (HDL) cholesterol were associated with lower rates of CHD incidence. This
was further confirmed via controlled clinical trials conducted to clear out controversy about lipid
hypothesis 4.

3

Figure 1.2: (A) death of part of heart muscle due to insufficient blood supply (B) Cross section
of coronary artery with plaque built up and blood clot 8.

1.2.

Coronary Artery Stenting (CAS)

1.2.1. Percutaneous Transluminal Coronary Angioplasty (PTCA)
A number of practices is well-established for the treatment of atherosclerosis in order to
restore coronary blood flow 9. For long time, coronary artery bypass graft (CABG) remained the
gold standard practice for coronary artery disease treatment. CABG, however, involves an
invasive intervention to bypass blocked artery using a graft harvested from other body parts. This
is accompanied by either during or post-surgery morbidity and mortality risks. In 1977, the first
percutaneous transluminal coronary angioplasty (PTCA) was performed to replace CABG as a
minimally invasive technique that spare CAD patients post-surgical risks and complications 1.
PTCA involves the insertion of a balloon-tipped catheter through a small incision at a major limb
artery. The catheter is guided over a thin radio-opaque wire that allows the procedure to be
visible under the fluoroscope x-ray imaging. Contrast agents are injected in the circulation
4

concurrently to locate the site of the blockage. Upon reaching the site of occlusion, the balloon is
then inflated to cause plaque compression and/or destruction, dilatation of arterial stenosis and
allows the blood flow restoration, then the balloon is removed 10, 11, see Figure 1.3.

Figure 1.3: Description of PTCA from site of catheter insertion till (A) reaching diseased site, (B)
Balloon inflation and (C) Blood flow recovery after balloon removal 12.

The success of the previously described plain balloon angioplasty was, however, threatened
by the risk of re-narrowing and possible need of emergency CABG. It was noticed that postprocedural arterial response involved 5% risk of acute restenosis during the first 24 hours, or 2050% risk of late occlusion during the first six months. After investigation, this was attributed to
tissue trauma during the mechanical restoration of blood flow and morphological alterations that
affected the arterial wall. Consequently, arterial smooth muscles undergo elastic recoiling and
negative remodeling takes place through a decrease in external diameter of the artery during
healing. To eliminate such serious complications, bare-metal stents (BMS) were introduced to
act as a residing scaffold to prevent arterial collapse incurred by plain balloon angioplasty

10,13

.

Stents are expandable wire-meshes in the form of tubes, which come in a wide range of designs

5

and materials, based on implantation procedure and patient's case. As shown in Figure 1.4, they
are used as a supporting structure to prevent the artery from collapsing after balloon angioplasty
to maintain blood flow 10,14.

Figure 1.4: Stent delivery mounted on a balloon-tipped catheter during PTCA. (A) Stent crimped
on deflated balloon, (B) stent expands with balloon inflation, and (C) balloon left in place after balloon
removal 15.

1.2.2. Drug Eluting Stents (DES)
After the introduction of BMS to the angioplasty procedure, patients' follow ups and clinical
studies showed that restenosis rates were only improved to 20% - 30% 16, while in patients with
complex lesions, such rates can go up to as high as 60% 11. Further investigation attributed the
renarrowing at the treated location to what is known as neointimal hyperplasia. Hardly
controllable intima reaction and hyper proliferation of the vascular-lining tissue led to in-stent
occlusion, which required medical re-intervention

10,14

. Clinical studies that investigated the

potential of avoiding this complication using systematic drugs such as antithrombotics and
glucocorticoids have generally failed

17

. In a more successful attempt to reduce the number of

patients that suffer from recurrent stenosis and clinical CHD, a therapeutic agent was introduced
locally on the stents platform to combat hyperplasia, offering what is known as drug eluting
6

stents (DES) 1. DES successfully emerged to revolutionize the field of intervention cardiology
with decreased restenosis rates below 10% 18. They became more preferred choice although they
were only introduced in 2003. By 2006, 8 out of 10 deployed coronary stents were DES 19, at an
annual cost between 4 to 5 billion USD 20.

The emergence and development of DES is considered a successful example of
multidisciplinary research that offers a life-saving solution to one of the most prevalent deathcausing problems worldwide. It combines the understanding of the restenosis biology,
pharmacology and appropriate drug selection, drug release and delivery strategies as well as
material in-depth studies

22, 23

.

The drug is meant to inhibit neointimal hyperplasia by

suppressing one or more processes involved in the biology of the restenosis. Accordingly,
therapeutic modalities of the loaded drug can be classified mainly into antiproliferative, antiinflammatory, migration inhibitors and immunosuppressive as well as prohealing and antithrombotic agents

24, 21

. These types of DES and most famous examples from each class are

summarized in Table 1.1.

Clinical evaluations have so far overwhelmingly showed strong evidence of DES superiority
over BMS in reduction of in-stent restenosis rates. However, cases of serious clinical events have
raised concerns over DES long time safety and efficiency 6. In particular risks of late and very
late stent thrombosis are considered 25. Several proposals have been offered to explain why such
technical marvels would turn to be thrombogenic. Some of the most supported reasons are; 1delayed endothelialization due to locally delivered cytotoxic or cytostatic drugs or other
pathological risk factors, 2- inherent thrombogenicity of the stent as a foreign body to blood
circulation, 3- hypersensitivity reactions related to the metallic material used for stent
manufacturing or/and polymeric coatings used as drug carriers, 4- dual antiplatelet therapy
(DAPT) early discontinuation, and 5- stent malapposition or incomplete apposition, related to
technical deployment 26–29.

7

Table 1.1: Types of DES and most famous examples from each class 21.

Anti-inflammatory

Anti-proliferative

Immunomodulators

Migration inhibitors,

Promote healing and

ECM* modulators

endothelialization

Dexamethasone

QP-2, Taxol

Batimastat

BCP671

M-prednisolone

Actinomycin

Prolyl hydroxylase

VEGF

Interferon γ-1b

Methotrexate

inhibitors

Estradiols

Leflunomide

Angiopeptin

Halofuginone

NO donors

Vincristine

C-proteinase

EPC antibodies

analogues)

Mitomycin

inhibitors

Biorest

Tacrolimus

Statins

Probucol

Advanced coatings

Mycophenolic acid

C-MYC antisense

Abciximab

Carvedilol

Mizoribine

Sirolimus

Statins

analogues)

Cyclosporine

RestenASE

Tranilast

2-chloro-

Biorest

deoxyadenosine

Abciximab

PCNA ribozyme

Sirolimus

(and

(and

Abciximab

Abciximab

*ECM: extracellular matrix, PCNA: proliferating cell nuclear antigen, VEGF: vascular endothelial
growth factor, NO: nitric oxide, EPC: endothelial progenitor cell

Accordingly, the Food and Drug Administration (FDA) has increased the recommended
duration for systematic DAPT to double it into at least one year, to reduce the incidence of late
stent thrombosis

30

. Such increase has multiple side effects such as high risk of bleeding,

complicated patient management after any surgical procedure and high costs. Therefore, current
research is concerned with improving DES performance and long-term safety, using different
approaches and multidisciplinary solutions that tackle any or all of the previously mentioned
causes of thrombosis, while sparing the need of long-term DAPT 6, 25.
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1.3.

Material Perspective for Stent Substrate
A wide range of different materials has been used in the manufacturing of stents. These

materials need to fulfill a number of rigorous properties; mechanical, physical and chemical
ones. According to procedure of implantation, long term application and safety, these properties
are strongly studied and directly affect the choice of stent

14

. An ideal stent has been described

with many characteristics in plentiful reviews. They should generally possess (1) low profile, i.e.
easily crimped on the balloon-tipped catheter for facile deliverability; (2) flexibility to travel
through narrow vessel whenever needed; (3) satisfactory radio-opacity to be visible for the
clinician during the procedure; (4) acceptable expandability ratio, i.e. as the balloon is inflated,
the stent should be able to expand sufficiently and conform to the morphology of the vessel; (5)
adequate radial strength supported by high tensile strength, i.e. stent should withstand imposed
force by the arterial wall and avoid collapsing; (6) biocompatibility to avoid platelets adhesion
and inflammatory reactions; (7) capacity to deliver drug locally to treated site; (8) compatibility
with magnetic resonance imaging (MRI). In addition, an ideal stent material would have high
elastic modulus to avoid recoiling, and low yield strength to expand during deployment at
acceptable balloon exerted pressure 16,31.

1.3.1. Permanent Stents
Medical implants in general are not only made of metals, but also ceramics and polymers.
However, ceramics and polymers lack few of the previously mentioned critical properties needed
for ideal stents, especially mechanical properties. Hence, metals are the main materials used so
far for the manufacturing of coronary stents. Combination of properties described above is
substantially difficult to meet in a single material. Therefore well studied compromise is always
essential to be found, and research is still intensively ongoing to tackle this issue 31.

1.3.1.1 Balloon Expandable Stents
The metals commonly used in the manufacturing of stents are 316 L stainless steel (SS),
cobalt-chromium (Co-Cr) alloys, platinum (Pt) alloys and Nitinol (Ni-Ti), which will be
9

specifically described in a later section, under "self-expandable stents". Table 1.2 summarizes the
main mechanical and physical properties of such materials. SS, Co-Cr and Ni-Ti alloys are
widely used in different biomedical applications due to their high corrosion resistance, high
elastic modulus and high ductility. Although other materials can show better corrosion resistance
and biocompatibility such as titanium (Ti) alloys, currently used Ti-alloys in biomedical field,
such as Ti-6Al-4V alloy, lack sufficient ductility, strength and density needed for coronary stents
16,31

. Further details are presented below describing 316L SS, Co-Cr alloy and Pt alloys as they

are the three most commonly used materials in manufacturing stents currently available in the
market and Ti alloys as they are crucial for the scope of this thesis.

Table 1.2: Mechanical and physical properties for selected biomaterials, used for stent manufacturing
16,31

.

SS 316L

Co-Cr (L605)

Nitinol

Pt-10Ir

Ta

Cp-Ti

Density (g/cm3 )

7.95

9.1

6.45

21.55

16.6

4.5

Elastic Modulus

193

243

90

150

185

107

UTS (MPa)

670

1147

1400

340

207

760

Yield Strength

366

629

195–690

200

138

485

43

46

14

25

25

30

(GPa)

(MPa)
Elongation (%)

Stainless steel (SS) is iron-based alloy that can be prepared in different grades used for
different applications, according to the desired properties. These grades are differentiated
according to the type and percentage of added elements that comprises the alloy along with iron.
These elements include Ni, Cr, Mo, Nb, Ti, and N, and they directly affect the alloy's strength,
microstructure and corrosion resistance. Although SS does not corrode in oxygen containing
environment. However, they may locally corrode in chloride containing media such as human
fluids 16,31,32.
10

Austenitic 316L SS has sufficient mechanical properties making it well-suited for stent
application and the main metal used for stent manufacturing for a long period of time, see Table
1.2. The corrosion resistance of SS is increased by adding up to 3% Mo, and up to 15% Ni, while
reducing carbon content below 0.030% 31,33. However, with such relatively high content of Ni as
well as presence of Mo and Cr, these ions can be released to the surrounding tissues causing
local immune response and allergic reactions, which would contribute significantly to in-stent
restenosis. Also, carbon content can result in the formation of carbides at the grain boundaries
reducing the corrosion resistance at those areas. Moreover, with more than 60% Fe content in SS
it possesses ferromagnetic properties that would clinically interfere with MRI that the patient
may need to undergo. While on the other hand, it has relatively low density that hinders
sufficient visibility during PCTA procedure. Therefore, the use of SS is dependent on the use of
coating material that would solve some of the challenges mentioned above, yet may not be able
to solve others 34,35.

Co- Cr alloys have been used broadly in biomedical applications for decades and have been
replacing SS stents commercially in the past few years along with Pt-alloys. They have
outperformed SS both during and post deployment

16,31

. As seen in Table 1.2, they have higher

density that makes them more radiopaque and facilitate guidance during angioplasty. They have
high tensile strength, which allows for thinner struts for better deliverability and lower rates of
stent fracture

36

. They are also characterized by high elastic modulus limiting stent recoiling.

Moreover, they demonstrate high corrosion and wear resistance, which reduce the risk of late
complications 37,38.

Pt alloys possess great potential in the field driven by their biocompatibility, anti- corrosion
and improved radiopacity 31. For example Pt-Cr alloy showed enhanced endothelialization, high
corrosion resistance and comparable mechanical properties to stainless steel due to its chromium
content 39. While Pt-Ir (90% Pt – 10% Ir), for example, showed enhanced radiopacity, reduction
in inflammatory reactions and incidence of thrombosis. However, they showed higher rate of
recoiling and their mechanical properties are still under question 40.
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Titanium (Ti) and its alloys have been widely used in biomedical field especially in dental
and orthopedic applications. They show excellent biocompatibility and high corrosion resistance
due to the oxide layer formed on their surface, which is highly stable. However, for coronary
stent manufactory, Ti application has been limited to bio-inert coatings that showed significantly
reduced thrombogenicity and intimal hyperplasia, such as Ti-nitride-oxide layer on Titan© stent
(Hexacath, France) 16,31,41

The reason why pure titanium or some of its common alloys are not used as stent material is
due to its mechanical properties that does not match the requirement of ideal stent. It has high
yield strength but relatively low tensile strength. Therefore, during deployment with balloon
expansion, they will need to expand to stresses beyond their yield strength. Furthermore, with Tialloy low tensile strength and low ductility, the stent will be easily prone to fracture. Using
materials in the alloy that would reduce its yield strength might be a good strategy to make it
mechanically acceptable, while keeping the original tensile strength. Some of the promising Tialloys for making stents are Ti-based Tantalum (Ta) and Niobium (Ni) alloys, which showed
outstanding haemocompatibility

42

. Also, Ni-Ti alloys are extensively used in stents

manufacturing at almost equal percentages of both elements. This will be briefly discussed below
under “self-expandable stents” section 43.

1.3.1.2. Self-expandable Stents
One of the stents classifications depends on method of deployment into the vessel during the
PCTA. Accordingly, they are classified into balloon expandable stent (BX) – as described
previously and shown in Figure 1.4 – and self-expandable stent (SX), see Figure 1.5. BX is
manufactured crimped and mounted on a balloon that inflates at the required site expanding the
stent along with the balloon inflation. SX is manufactured at or slightly above vessel diameter
then constrained in the crimped state within a sheath till it reaches site of delivery 44. Therefore,
materials used for BX should have the ability to undergo plastic deformation during deployment,
and then preserve required size once positioned. However, materials for SX should have enough
elasticity to be compressed while delivered, and then expand in place

14,16

. And it is fair to say

that balloon expandable stents resist balloon expansion, whereas self-expandable ones assist it.
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Figure 1.5: Self-expandable stent; introduced crimp within a sheath. After reaching delivery site,
sheath is removed and the stent expand to its original shape 45.

BX can suffer from mechanical failure and collapse if subjected to external pressure that
exceeded its critical value. While on the other side, SX will not suffer from same strength
limitation by virtue of its elastic properties that permit its radial recovery. Also, SX was found to
be superior to BX in maintaining vessel radial compliance after stenting, which is a measure of
yielding to pressure without disruption. Therefore, if a healthy vessel would have 6%/100 mmHg
compliance normally, this number would be 3-4%/100 mmHg compared to less than 1%/100
mmHg compliance after SX and BX stenting, respectively. Furthermore, bending compliance is
higher for SX, which gives an advantage at both delivery and deployment. This leaves the stent
more conformable and adaptable to vessel shape avoiding high stresses at the end of the stent,
which may contribute to intimal hyperplasia. However, on the other hand, concerns regarding SX
are still raised due to risk of acute recoil with calcified lesions, recovery from buckling with
large stents and placement technical challenges 44,46.

One of the most widely used materials for self-expandable stent manufacturing is Nitinol
(Ni-Ti alloy). It consists of approximately equal atomic amounts of both nickel and titanium;
49.5-57.5% wt% Ni and the rest is Ti

16,31

. They have unique mechanical properties that highly

favor their use in SX, such as shape memory and superelasticity. Shape memory effect allows the
material to return from its deformed shape into its original one by heating. Superelasticity allows
apparent plastic deformation to return to original shape when load is released. Nitinol SX are
13

manufactured at a size slightly higher than vessel diameter. They deform plastically under room
temperature and are crimped onto delivery system. Under the effect of body temperature, they
expand to regain their original shape conforming to the vessel diameter. As shown in Figure 1.6,
Nitinol has similar behavior to natural body structural materials such as bones, hair and tendons.
These materials can be deformed elastically up to 10% strain. Such strain can be recovered at
lower stresses after the release of the stress, and loading/unloading curves are characterized by
the so called hysteresis 31,43.

Figure 1.6: Mechanical compatibility of Nitinol with body structural material 43.

1.3.2. Biodegradable Stents
Basically, stents are supposed to function as a mechanical support for the blood vessel and
prevent acute recoiling until endothelial tissue is regenerated and regain its integrity. Hence, the
stent role is temporary and long term existence can be unnecessary. The concept of
biodegradable stent became, therefore, very appealing and drew the attention of research
community as well as stents industry. It spares patient from long term complications such as
risks of in-stent restenosis, late stent thrombosis, persistent vessel stiffness and incompatibility
with future interventions 47.
14

Ideal biodegradable stent material should be able to compromise mechanical integrity versus
degradation on implantation site. As shown in Figure 1.7, degradation would begin theoretically
at low rate when mechanical integrity is still needed and maintained. After a period of 6-12
months, vessel remodeling is believed to be completed, hence higher rate of degradation
thereafter is acceptable. Two classes of materials are used for biodegradable stents; metallic
materials such as Mg- or Fe- based alloys, and polymeric materials such as lactic, glycolic and
caprolactone families. Although biodegradable stents witnessed high research and market
interest, many concerns are yet to be evaluated and answered before replacing current
technology. These concerns include safety issues regarding degradation products and
degradation mechanism 48, as well as practical implication of mechanical compromise over time
that was discussed above.

Figure 1.7: Theoretical material biodegradation over time, versus its mechanical integrity 47.
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1.4.

Surface Treatment

1.4.1. Polymeric Coating
Coatings have been initially used to enhance the biocompatibility of stent materials within
vascular environment. Later, they were used as vehicle for drug loading and a platform to offer
advanced solution for better endothelialization. Currently, the most widely used coating
materials for different types of stents are polymeric coatings

16

. Permanent polymer coatings,

which have been used initially for DES, showed impaired vascular healing and were found to be
responsible for inflammatory responses due to permanent contact with the arterial wall

49

. It

carried the blame on late stent thrombosis along with other patient and lesion related factors 50.

Biodegradable polymers have, therefore, appeared to be an appealing alternative to durable
polymers as stent coating. They are more likely to avoid chronic inflammatory response and long
term complications, as they degrade over certain amount of time and their degradation product
theoretically get washed out from human body. Materials used for such coatings may include
poly lactic acid (PLA), poly lactic-co-glycolic acid (PLGA) and poly caprolactone (PCL)

48

.

Drug release is controlled with these materials based on their degradation profile over time.
Challenges are though still remaining for advancement in polymeric coatings. These challenges
include for example; establishing optimal formulation and degradation time, pharmacokinetics of
drug release during degradation and fate of degradation by-products.

50

.

1.4.2. Nanoporous Surface
Reference to polymer-related concerns described above, porous platforms offer a promising
step forward in the advancement of DES as polymer-free surfaces. They avoid polymer long
term inflammatory responses, improve healing process, improve surface integrity by avoiding
polymer peeling and can still act as drug reservoirs. Moreover, they were found to promote rapid
endothelialization. This was first investigated by creating micropores on the vascular graft wall,
as shown in Figure 1.8, using different techniques 51–53.
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Figure 1.8: VESTAsync DES system. Top images picturing stent struts at different magnification
and bottom ones are SEM (Scanning Electron Microscopy) images of their microporous Hap (Hydroxy
apatite coating 51.

It was found that increased pore density resulted in an enhanced endothelialization and
formed thinner intima

54

. Also to better control sustainable release of the drug from the porous

reservoir and avoid burst effect, smaller pores may be required to retard quick release 16. Hence,
the use of nanotechnology advances in stents surface treatment is investigated in attempt to fulfill
such favored requirements. It involves the design and development of structures and materials
with at least one dimension ranging in size between 1- and 100- nanometer. Such size allows the
structure to manipulate matter at its atomic scale, offering exceptional opportunities at biological
interfaces. Using nanoporous assemblies on surface of graft material not only act as drug
reservoir but also play a critical role in fast healing 55.
The concept certainly have merits and their positive influences on tissue regeneration have
been already explored for different medical devices, however, research is still extensively
required to study the potential use of this kind of surface treatment. Concerns that still need
answers include; thrombogenicity of such rough surfaces, mechanical performance during and
after deployment, drug-release profiles of different morphology and preparation techniques for
controlled morphologies on the surface of different biocompatible materials 38.
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1.4.3. Other Surface Treatment
A wide range of other coating types has been explored for stent material for different
functional advantages

38

. For example, 1- anti-corrosive metal oxides such as titanium dioxide,

significantly decrease metal ion release from core material enhancing biocompatibility; 2- silicon
carbides that allow electron transfer between the metallic surface of the stent and blood proteins
to reduce in stent fibrinogen deposition and stent thrombosis; 3- carbon coating for lower rates of
metal ion release and platelet aggregation; 4- titanium- nitride-oxide coating as barrier against
metal ion and to regulate endothelialization; 5- endothelial cells seeding on stent surface to
promote endothelialization and fast healing; 6- biotechnology advances that use anti-endothelial
progenitor cells (anti-EPC) in contact with blood flow to capture EPCs, which are seed for
endothelial tissue growth, promoting controlled tissue growth (see Figure 1.9). Some of those
previously mentioned approaches are proven clinically insignificant or even failed avoiding late
complications, while others are being currently adopted commercially and considered state-ofthe art material treatments, which are beyond the scope of this thesis and discussed efficiently
elsewhere 16,25,29,31,38,50.

Figure 1.9: EPCs capturing technology by Genous ® stent for enhanced endothelialization 56.
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Thesis Scope and objectives
Reference to the challenges facing Drug Eluting Stents (DES) described earlier in this
chapter, we can summarize saying that ideal surface properties for DES should offer the
following:
(1) Material biocompatibility.
(2) Pro-healing bioactivity to avoid neointimal hyperplasia, while promoting control
endothelial healing.
(3) Capacity for drug loading.
(4) Mechanical integrity.

With the aim to fulfill these objectives, nanoarchitectures were investigated in this thesis as
surface treatment for potential biocompatible DES material. As will be elaborated in chapter 2,
nanoporous structures and nanotubes arrays were found to be very promising for enhancing
tissue regeneration and as drug loading vehicle to be used for wide range of biomedical
applications. For extending and supporting these efforts to be used for intravascular stents the
following work will be covered in this thesis.

(1) Fabrication of nanoarchitectures on the following materials, a) pure titanium, b) Ti-45Ni
alloy and c) Ti-17Nb-6Ta which possesses mechanical properties matching with those required
for self-expandable stents.
(2) Studying different properties for fabricated nanoarchitectures through various
characterization techniques. Characterization would include; morphological, mechanical,
compositional and structural.
(3) Investigating the effect of different nanoarchitectures as surface treatment on biological
response. And comparing their bioactivity versus smooth surface of the same material. This will
be assessed through in-vitro studies using vascular endothelial cells.
(4) Studying the drug loading capacity of different morphologies.
(5) Calculating drug release profile for the most promising nanoarchitecture using
computational simulation.
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Chapter 2: Literature Review
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Chapter 2: Literature Review
2.1. Formation of Nano-tubular Anodic Oxide Layer on Ti and Ti-alloys
There has been an amplified interest recently in exploring nanoscale surface topography for
implantable devices such as dental and orthopedic prosthetics, grafting materials and
intravascular stents – as will be described below

57

. Titanium and titanium alloys possess

superior properties relative to many other materials in terms of biocompatibility, corrosion
resistance, specific densities as well as mechanical properties that are tuned with alloy material
and according to the intended application

57,58

. Consequently, nanotubular oxide structures

formed on the surface of titanium and its alloys have been extensively investigated for enhancing
the performance of biomedical implants, especially TiO2 nanotubes 57- 66.

Different techniques have been used for the fabrication of these structures such as sol-gel,
atomic layer deposition, hydro/solvothermal methods and micelle templates

59–66

. However,

among these methods, one technique showed superior control on the dimensions and
morphology of the nanostructure, which is electrochemical anodization in fluoride-containing
electrolytes. It is also relatively simple, scalable, cost-effective and applicable for complexshaped base material

67

. Early report of achieving self-organized TiO2 nanostructure using

anodization was by Zwilling, et al in 1999 who produced nanoporous assembly of TiO2 on Tibased alloy in acidic medium

68

. In 2001, Gong, et al first reported the formation of highly

ordered TiO2 nanotube array by anodizing titanium in dilute HF electolyte 69. Efforts to optimize
these nanotube arrays have been ongoing for more than a decade now to be used for a wide range
of promising applications. It was found that anodization process, and accordingly the final
surface nanomorphology and composition, are drastically affected by anodization conditions,
such as, applied potential, time, pH and fluoride species concentration

67

. Some of these efforts

are summarized in Table 2.1 below.

Since the work of Grimes, et al in 2001, the development of TiO2 is grouped into three
generations reference to the nature of the electrolyte used. First generation TiO2 nanotubes were
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achieved by aqueous HF based electrolytes, see Figure 1.2. They are characterized by relatively
short length with maximum of 500 nm 69,70.
Table 2.1: Summary of titania nanotubes properties under different anodization conditions 71.

Length

Wall

Diameter

Voltage/

Time/

Main

Conditions

Ref.

/µm

Thickness/

/nm

V

h

solvent

22

10

6

H2O

0.5% HF + acetic acid (7 : 1)

72

65

20

10

EG*

0.2M NH4F+0.1M H3PO4+2% H2O

73

H2O

0.5% HF + acetic acid (7 : 1)

74

Glycerol

0.5 wt% NH4F

75

nm

0.12

9

1.76
0.36

17

46

12

0.50

˂10

150

5–15

4

3.5

60

EG

0.25 wt% NH4F

18

20–60

EG

0.25 wt% NH4F

0.5

15

100

20

2

H2O

0.5 wt% NH4F

76

1.9–5.7

8

30

20

16–70

GL

0.5 wt% NH4F

77

6

20

110

H2O

0.1 M KF + 1 M NaHSO4 0.2 M

78

trisodium citrate sodium hydroxide
˂20

10

15-110

15

20-50

1

EG

0.25 wt% NH4F 10 wt% H2O

79

50

12

EG

0.25 wt% NH4F

80

EG

0.25 wt% NH4F 2 vol.% H2O

81
82

7-35

15

130

60

134

25

160

60

17

EG

0.25 wt% NH4F

45

15

120

40

69

DMSO**

2% HF

93

-

200

60

70

DMSO

2% HF

220

50

110

50

17

Formamide

NH4For HF, 2% H2O

83

360

20

120

60

96

EG

0.3 wt% NH4F, 2% H2O

84

380

168

0.3 wt% NH4F

538

168

0.4 wt% NH4F, 2.5% H2O

1000

216

0.3 wt% NH4F, 3.5% H2O

*EG: Ethylene Glycol
** DMSO: Dimethyl Sulfoxide
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For the second generation, nanotube length was increased up to 7µm. This was achieved by
controlling the electrolyte pH and accordingly the chemical dissolution of TiO2 during the
process of anodization. In 2004, Grimes, et al used electrolyte solution containing sodium
fluoride (NaF) or potassium fluoride (KF) to produce nanotube arrays that would belong to the
second generation. They adjusted the pH to 4.5 using sulfuric acid, sodium hydrogen sulfate,
sodium hydroxide and/or citric acid. They were able to produce nanotubes up to 4.4 µm, see
Figure 2.1 85. One year later, Grimes, et al were able to again produce longer nanotubes – relative
to first generation – using different electrolytes and conditions. They used 1:1 flourinated
dimethyl sulfoxide (DMSO) and ethanol to produce nanotube arrays of 2.3 µm 86.

Figure 2.1: SEM images for TiO2 nanotubes arrays for (a) first generation 69, (b) second generation 85, (c)
third generation 82
23

Third generation of TiO2 nanotubes array was achieved in later work by processing in nonaqueous, polar organic electrolytes such as ethylene glycol and formamide, reaching tubular
length of up to 1000 µm. In 2006, Grimes, et al succeeded to produce nanotube array up to 134
µm in length, see Figure 2.1. They used a variety of polar organic electrolytes as mentioned
earlier, along with fluoride ion donor as KF, NaF or HF. They reported that the key to successful
fabrication of long arrays is in keeping water content below 5% 82. This was followed by several
successful attempts to produce arrays of length above 100 µm. In 2007, they reported for the first
time self-aligned nanotube arrays of titania about 1000 µm in length and 10 000 aspect ratio,
using NH4F and ethylene glycol-based electrolytes

84

, see Figure 2.2. Finally, fourth generation

is suggested to be one with fluoride-free electrolyte chemistries 87.

Figure 2.2: SEM images of the first reported nanotube arrays of length 1000 µm (third generation)
using organic electrolyte. (a) top view, (b) bottom/barrier view, (c), (d) cross-sectional view 84.
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In addition to morphological characteristics of the titania nanotubes arrays, their properties
depend on the crystallinity and isomorph type. This directly affects its utility for different
applications, including efficiency at biological interfaces in biomedical applications. Asfabricated nanotubes are amorphous. Upon annealing in oxygen at elevated temperatures, tube
walls are converted into anatase and rutile phases, respectively. As the anodization voltage
increased, amount of anatase formation becomes higher

88–92

. The rutile phase initially starts at

the interface between the nanotube arrays and the support. At elevated temperatures (above 550
o

C), rutile crystallites merges with the nanotubes and transforms into compact rutile layer as

temperature reaches 800 oC 93.

In-application efficiency also relies on the integrity of the titania nanotubes layer at the
functioning site. Unfortunately, weak adhesion has been reported between the nanotubes layer
and the metallic substrate, leaving them prone to be peeled of easily

94 95

,

. Therefore, several

attempts have been conducted to understand the main cause of such phenomenon and offering
practical solution to it. Schmidt-Stein, et al thermally treated TiO2 in acetylene atmosphere to
transfer it to its semi-metallic form (TiOxCy). They explained that incorporating carbon to its
microstructure enhanced the layer's mechanical strength 96. Xiong, et al annealed TiO2 nanotubes
for different time durations and reported that adherence improved actually with annealing time
97

. Recently in 2014, Yu, et al introduced 200 nm thick oxide layer near the nanotube bottom by

adding fluoride-free anodization step prior to the main anodization process, see Figure 2.3. They
introduced this approach to reduce the fluoride rich TiO2 layer found at the interface with
metallic substrate that is believed to be responsible for poor layer adhesion. They reported that
this approach, increased adhesion strength almost three folds 98.
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Figure 2.3: SEM images of top view on the left and side view on the right of titania nanotube arrays
(c,d) with and (a,b) without additional oxide layer by fluoride free anodization 98.

The same principle of using electrochemical anodization technique was extended to titanium
alloys for producing oxide layer of nano-scaled topographies

67

. In fluoride-containing

electrolytes, fabrication of nanostructured oxide layer for titanium alloys using anodization
technique was tailored for wide range of alloys with endless virtual possibilities, to be used in
different applications; some of which are summarized in Table 2.2 below.
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Table 2.2: Summary of TiO2 nanotubes’ properties made from alloys under different anodization
conditions 71.
Alloy

Ti45Nb (45 wt% Nb)

Length

Diamete

/ µm

r/nm

2.9

60

Vol/V

20

6.3

Time/

Main

Conditions

Ref.

min

solvent

120

water

1 M NaH2PO4, 0.5 wt% HF

99

EG

0.05 M HF

100

20h

TiMo (7 wt% Mo)

4-16

15-45

20-60

Ti–0.2 wt% V

1

120-130

60

15-20

EG

0.2 M HF

101

TiNb (0.1 wt% Nb)

1-15

50-65

50

5-120

EG

0.1 M NH4F+ 1 M H2O

102

Ti–0.2 wt% W

1.1-1.2

85-95

120

10

EG

0.2 M HF

103

Ti–3 wt% V
Ti–18 wt% V

Ti–9 wt% W
TiN

12
650

20-80

20

120

104

Glycerol + 0.27 M NH4F
water

Ti -45wt% Nb

50

20-50

Ti- 35wt% Ta

50

30-90

Ti- 50wt% Zr

30

10-15

40

˂1

Cl-

0.05 M NaClO4 +0.05 M

perchlorate

NaCl in 50:50 vol% of

105

H2O:C2H5OH

Generally, the composition of the oxide layer and the ratio of materials, directly reflect the
properties of the alloy. This was demonstrated by Kamkin, et al for anodic oxide films on
titanium-aluminum alloys. They showed that the mainly amorphous oxide film consists of TiO2
and Al2O3 mixture with ratios perfectly consistent with the alloy matrix

106

. This phenomenon

was likewise observed for TiTa alloy by Jha, et al. However, they also reported another behavior
observed for other alloys, such as TiNb and TiZr. These alloys showed mixed oxides in the
anodized layer along with oxides of individual components, as shown in Figure 2.4

105

. On the

other side, full conversion of the anodized surface into mixed oxide was reported by Yasuda, et
al for TiZr alloy, as shown in Figure 2.5 107.
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Figure 2.4: XRD spectra of oxide nanotubes for different titanium alloys, before and after annealing.
Oxides from (a) TiNb alloy, (b) TiZr alloy, and (c) TiTa alloy 105.

Figure 2.5: XPS spectra of (a) O 1s, (b) Ti 2pa (c) Zr 3d, for the as-grown and annealed nanotubes of TiZr
alloy 107.
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2.2. Biological Response of Nanotopography on Surface of Titanium and
Titanium Alloy
The response of biomaterials entirely depends on biocompatibility and surface properties.
Hence, beside the choice of substrate material, paying attention to surface treatment is crucial for
all biomedical applications

108

. As mentioned earlier, nano-architectures have been extensity

studied as surface treatment for biomaterials. They are considered as biomimetic interfaces that
accordingly provide solutions to few biocompatibility challenges and enhance tissue regeneration
57

. Experimental evidences have recently been accumulated to show the importance of surface

topography of biomaterials at the nanoscale and its effect on biological microenvironment 109.

For orthopedic implants, this has been studied for years now and positive effects of
nanostructures on tissue adhesion and regeneration are well-established. This motivated the
exploration of those structures for other applications in contact with human tissue or blood
components such as intravascular stents. Minagar, et al reported that bone cells response to
implant material is affected by topography, mechanics, physicochemical and electronics of
implant surface 110. Hence, as suggested by Webster, et al the bioactivity of the implants can be
considerably improved using nanostructured oxide materials

111

. Hamlekhan, et al further

elaborated that anodized nanotubular surfaces were found to promote osteoblast cell adhesion,
hydroxyapatite growth, improved integration and proliferation. This is attributed to increased
surface area offering more area for cell interaction, protein adsorption, surface energy as well as
increased hydrophilicity 112.

Oh, et al studied MC3T3-E1 cell growth and proliferation on TiO2 nanotubes array versus
pure Ti. Cell growth on TiO2 nanotubes substrates was found to be much faster. This was
justified by the surface area presented by the nanotubes pores and in-between gaps that offered
ions, proteins and nutrients continuous supply

113

. Effect of pore diameter on osseointegration

was an area of investigation for many research groups. Wang, et al studied diameter effect on
mechanism of biological attachment of implants to surrounding tissue. They used 30, 70 and 100
nm nanotubes structures with in-vivo implants and observed histological features of bone
surrounding the implant. Best results were reported for 70 nm diameter nanotubes 114. Kang, et al
29

also studied osseointegration over the same range of diameters. Highest values were also
reported for 70 nm after 4 weeks. However, higher values with 30 nm nanotubes structure were
observed after 12 weeks 115.

Almost 2 decades ago, Steele, et al have reported that protein adsorption is higher on
hydrophilic surfaces than hydrophobic ones

116

, which presents a critical step in cell adhesion

and implant bioactivity. Giordano, et al demonstrated that TiO2 nanotube formation on the
substrate surface decreased water contact angle (WCA) 117. Therefore, in order to enhance tissue
integration, adhesion and proliferation efforts have been accordingly exerted to increase
hydrophilicity of the implant surface. Terriza, et al induced superhydrophilicty on titania layer by
light using UV illumination. They reported highly enhanced cell attachment on immediately
illuminated titania surface

118

. Chang, et al studied titania nanotube contact angle at different

anodization time (5, 20, 40, 60, 90 min and 24 hrs) at constant voltage (30 V) and at different
annealing temperatures (no annealing, 300, 400, 500 0C). They reported that contact angle
decreased with increasing anodization time, as shown in Figure 2.6, and increasing annealing
temperature

119

. Also, it was reported by Uchida, et al that anatase phase of titania nanotubes

after annealing is much more efficient for nucleation and growth of bone tissue. This is attributed
to its ability to promote growth of hydroxyapatite layer 120.

Figure 2.6: Contact angle of titania nanotubes surface versus anodization time 119.
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Influence of nanoarchitecture on bioresponse for intravascular stent surfaces are not as
thoroughly reviewed in literature as for orthopedic prosthesis. Yet, a significant number of
research groups have investigated the effect of rough topographies on stent surfaces for almost
two decades now, and attention has been paid lately to nano-scale treatment. Back in 1997, De
Scheerded, et al suggested that stents with electropolished smooth surfaces are less thrombogenic
than non-polished ones. This was demonstrated on a rat AV (atrioventricular) model and a
porcine coronary model using an electropolished sample versus untreated one. Total weight of
the formed clot was found to be much lower with electrochemically polished sample 121. Tepe, et
al used an in-vitro model with human fresh whole blood to study hemoresponse of
electropolished stent surface reaching the same conclusion. It was found that platelet activation
and thrombogenicity was reduced on such treated samples versus smoother ones

122

. These

reports can significantly discourage the use of rough surface in stent applications, despite its
promising potential for offering polymer-free drug loaded surfaces.

However, on the other side, Palmaz, et al were able to demonstrate faster endothelialization
on stent surface decorated with parallel grooves at the microscopic scale than smooth
counterpart. This was studied using in-vitro culture of endothelial cells

123

. They, furthermore,

confirmed their results using in-vivo studies through placing sample stents in porcine carotid
arteries

124

. They explained stating that microscopic grooves assisted endothelial cell (EC)

migration to stent surface, which was found to be more influencing in endothelialization than EC
proliferation

125

. This fast endothelialization on rough topographies was found to significantly

reduce rates of thrombosis as well as neointimal hyperplasia. However, delayed
endothelialization with their smooth counterpart has been linked with late intravascular
complications

26,126–130

. These findings strongly supported studies that were extensively

undertaken on stent rough surface treatment for enhancing drug eluting stents.

These efforts were initially invested in studying the biological interaction of microporous
surface architectures fabricated by different techniques. Doi, et al demonstrated positive
influence of microporous polyurethane surface treatment on endothelial tissue response using invitro analysis 131. Also, Nakayama, et al supported this data by in-vivo studies. They covered the
stent surface with microporous elastomeric film – fabricated by laser ablation – with
31

immobilized FK506 for prevention of neointimal hyperplasia. After one month implantation in
rabbits, no significant lumen loss or hyperplasia was observed

132

. Dibra, et al performed an in-

vivo evaluation as well but on human sample, they conducted a randomized double blind study to
investigate the influence of stent surface topography on patient outcome after stent implantation.
They used 316L SS stent roughened with sand blasting into 0.09 and 0.21 µm minimum and
maximum root mean square roughness reference to a smooth surfaced stent. Data reported from
this study encouraged the use of rough surface treatment not only due to ability to significantly
reduce late lumen loss versus smooth reference, but also due to its potential to be used for
storage of anti-restenotic drugs

133

. Transferring micro-scale stent surface treatment into the

market, Yukon™ stent was released by Translumina, Hechingen, Germany. Post marketing
clinical data demonstrated comparable performance with other well-established stent (Taxus),
while failed to prove non-inferiority with another (Cypher). Therefore, long term efficacy and
safety of Yukon stent is still under question and investigation.

For higher pores density, larger surface area, more controlled drug release profile and better
biomimicry, nanoporous surfaces on stent materials became highly attractive for investigation
134

. Wieneke, et al coated a 316L SS stent with aluminum thin layer then electrochemically

converted it into nanoporous structure with pore diameter from 5 to 15 nm. They investigated the
effect of this architecture loaded with tacrolimus drug on the biological response of surrounding
tissue. They reported that the coating as well as loaded drug resulted in a positive synergistic
effect reducing the local inflammatory response and intimal hyperplasia, as seen in Figure 2.7
135

. This led to the release of Jomed™ stent into the market of intervention cardiology

136

.

However, Kollum, et al carried out in-depth investigation to assess the effect of this nanoporous
aluminum coating on in-stent restenosis, using porcine restenosis model. Particle debris was
found to be shed from the coating into the media and the intima, resulting in augmented
inflammatory response. This can potentially counteracts the effect of the antiproliferative loaded
drug resulting in neointimal hyperplasia and late lumen loss, see Figure 2.8 137.

32

Figure 2.7: Inflammatory cells migration to stent strut. A) Bare metal stents. B): with Al 2O3 coating.
C): with Al2O3 coating loaded with tacrolimus 60 µg. D): with Al2O3 coating loaded with tacrolimus 120
µg 135

Figure 2.8: Cross sectional histomorphometric images of porcine arteries 4 weeks after implanting A)
bare stents, B) aluminum oxide ceramic-coated stents, C) aluminum oxide ceramic-coated stent eluting
FK506 (50 µg) D) aluminum oxide ceramic-coated stent eluting FK506 (180 µg) . Presenting: A) thin
neointima; well healed. B) Thick neointima with fragments of ceramic stent coating present (arrow,
right). C) moderately thick neointima; well healed with fragments of ceramic stent coating (arrow, right).
D) neointima; well healed and similar in area to bare metal stent with fragment of ceramic stent coating
(arrow, right) 137.
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On the other hand, the use of TiO2 nanotube arrays for stent surface treatment showed highly
promising biological response that has driven its thorough investigation for the last few years.
Jin, et al have reported in 2008 an enhanced endothelial cells migration, faster proliferation and
increased reliability in the presence of TiO2 nanotubes. They underwent in-vitro analysis using
bovine aortic endothelial cells (BAEC) to compare between flat Ti surface versus nanostructured
oxide counterpart. They observed enhanced focal cells adhesion, contact stimulation and an
upregulated antithrombotic state with the nanoarchitectured surface, see Figure 2.9 138.

Figure 2.9: BAECs viability on flat Ti (upper panel) versus TiO2 nanotubes (lower panel) after
different time intervals (6, 12, 24, 48 hours). Cell survived over the two substrated, however, it showed
more flat monolayer of cells on nanotubes at 48 hours versus aggregated and relatively disrupted ones on
flat Ti at the same time 138.

In 2009, Mark, et al used another in-vitro model to study the impact of TiO2 nanotubes on
biological response of stent materials. The model involved studying the cellular activity of
mesenchymal stem cells (MSC) on the nanoarchitectures. They examined the influence of not
only surface geometry, but also surface chemistry and crystallinity. Their data reported
significant dominance of effect of geometry over other parameters on biological response. Data
supported better cells migration, adhesion and proliferation on TiO2 nanotubes versus smooth
surface. Furthermore, they observed enhanced MSC differentiation on nanotubes with smaller
diameter (15nm) as compared to larger diameters (about 100nm), see Figure 2.10 109.
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Figure 2.10: MSC adhesion to 15 and 100 nm TiO2 at high and low F- content at 2 time intervals 109.

These findings were supported by Desai, et al by immunofluorescence staining, SEM
imaging, proliferation assay, and immunoassay using endothelial cells (EC) and vascular smooth
muscle cells (VSMC) cultures. Results suggested that nanotopography may influence EC and
VSMC in a manner useful for vascular stents applications. As shown in Figure 2.11, TiO2
nanotubes promote EC proliferation, which would result in faster healing, while does not support
VSMC proliferation, which would result in lower risk of neointimal hyperplasia

139

. One year

later they further reinforced these data using gene expression analysis. Microarrays indicated
positive effect on EC proliferation and favored negative effect on VSMC proliferation, and
expression of inflammatory precursors and well as coagulation involved molecules 140.
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Figure 2.11: Ratio of 5-ethynyl-20-deoxy- uridine (EdU) positive, which is incorporated to detect cell
proliferation according to the assay protocol. (A) ECs, (B) VSMC on nanotubes versus smooth muscles,
normalized by the average proportion of positive cells on flat surfaces on day 1 and 3. Data is presented
as average + or - standard deviation. *p<0.05, **p<0.01 versus same day flat control, n=6 139.

As blood contacting biomaterials, hemocompatibility is an essential property to be
investigated for TiO2 nanotubes as part of evaluating its biological response. Smith, et al have
investigated the adhesion and activation of platelets, clotting kinetics of whole blood and key
blood serum proteins adsorption on titania nanotubes arrays. Their initial results reported high
protein adhesion, platelets activation and whole blood clotting kinetics. However, they
highlighted that hemoresponse is highly affected by surface geometry and can be altered and
adjusted by controlling tubes size parameters, which required further proper investigation in this
area 57. On the other hand, Menon, et al suggested that enhanced proliferation of endothelial cells
on grown TiO2 nanotubes would consequently contribute to hemocompatibility through
regulating platelet activation and accordingly reducing the risk of thrombosis. This was
elaborated by highlighting that one of the main roles of endothelial cells is to secrete antithrombogenic products such as nitric oxide (NO) and prostaglandin I2 (PGI2), which help
maintaining vascular homeostasis 141.
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2.3. Nanoarchitectures as drug reservoirs
As mentioned previously, the great interest of using nanoscale topographies on the surface of
biomaterials is not only driven by their ability to enhance biological response, but also by their
high potential to be used as drug reservoirs for local drug delivery. Choice of the drug active
ingredient is directly related to the application and site of biomaterial implantation. For example
local delivery of antibiotics is applied for orthopedic implants to ensure environment sterility and
ensure proper healing. On the other side, for intravascular stents, for example, cytotoxic drugs
are mostly delivered locally to avoid neointimal hyperplasia and preserve blood flow. Local drug
delivery does not only target the dosage to the site of application but also avoid higher risks of
side effects associated with systematic drug intake

142,143

. Nanoarchitectures as local drug

delivery systems can offer a number of advantages over few of currently followed techniques; 1)
It can be grown on material whose biocompatibility has been well-established and already
widely used for biomaterials such as titanium and titanium-based alloys, 2) synthesis techniques
can provide a control over the surface structure's size and morphology, offering potential control
over release kinetics, 3) nanoarchitectures can be fabricated on 3 dimensional (3D), non-planar
surfaces, hence being adaptable to a variety of implant technologies, 4) and surface wettability
can be easily controlled 143.

For intravascular stents, local drug delivery using nanoarchitectural reservoirs was first
investigated by Wieneke et al in 2003. They used nanoporous anodic aluminum oxide (AAO) to
release tacrolimus for studying rabbit intimal proliferation

135

. Positive results have driven the

interest of Kim et al in 2007 to further investigate the drug release kinetics from such structures.
316 SS stents were coated with nanoporous anodic aluminum oxide (AAO) fabricated via
anodization, which have different tubes dimensions (diameter and length). 2-deoxyadenosine
drug was loaded to the (AAO) coated sheets by immersion in drug solution for certain amount of
time. In-vitro drug release was investigated in phosphate buffer saline (PBS) using high
performance liquid chromatography (HPLC). It was observed that drug release is directly
proportional with nanotubes pore diameter, while inversely proportional with their depth, see
Table 2.3 144. In another study, Kim et al used lipophilic paclitaxel drug loaded in the same AAO
platform to study its release kinetics, versus the hydrophilic 2-deoxyadenosine. Paclitaxel release
37

from different nanotube diameters and depths showed that amount of drug released did not
depend on pore diameter but varied inversely with depth, see Figure 2.12 145.
Table 2.3: Amount of drug release/µg from AAO film 144.

Diameter (nm)
26.46

13.5

19.7

Time
(hour)

13

27.2

Depth (μm)
1.33

0.943

1.4

3.2

4.4

2

500.97548

397.58979

197.72221

573.01701

304.32572

5

3.15701

3.00

0.93224

2.81911

2.39437

11

0.75078

0.4815

2.17619

0.3778

0.37863

23

0.9379

0.40268

0.93244

0

0
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1.08203 0 0

0

0.49764

0

0

95

0

0

0

0

0

143

0

0

0

0

0

Figure 2.12: Cumulative release of paclitaxel from AAO with different pore diameter (to the left) and
depths (to the right) 145.

However, data on biological studies of nanoporous alumina versus titania nanotubes
described earlier could possibly indicate better in-vivo response with titania nanoarchitectures 146.
This encouraged their in depth investigation as drug reservoirs for a number of applications
including intravascular stents, some of which are summarized in Table 2.4 below. This was early
studied by Ayon et al using nanoporous TiO2 to load dexamethasone drug with target value
38

comparable to dexamethasone-eluting BiodivYsioTM stent. They reported that with fabricated
structural dimensions, one step loading resulted in unfavourable value of loaded drug with 70
ng/mm2 versus target of 500 ng/mm2. However, subsequent and sequential drug loading
procedure would increase total loaded amount and potentially reach desired target, as seen in
Figure 2.13 below 147.

Figure 2.13: Amount of loaded dexamethasone per sequential loading, using HPLC 147.

Popat, et al investigated the use of TiO2 nanotubes as another nanoarchitecture that can act as
drug reservoir. Through fabrication strategies, they offered better control over drug loading
capacity and release kinetics through controlling nanotubes dimensions. In one study, they
fabricated TiO2 nanotube arrays of 80 nm pore diameter and 400 nm in length for loading
Gentamicin antibiotic to avoid bacterial infection at site of bone implants. They reported that 7085% of the drug was retained in the nanotubes after washing. For drug release they reported that
total time needed for all drug to be eluted from the array is directly proportional to the initial
loaded amounts, with total time of 45, 90, 150 minutes taken to release 200, 400, 600 μg
gentamicin respectively 148. In another study, Popat, et al studied the drug release rate by varying
the loaded amount and the drug molecules polarity. They used two different loaded
biomolecules; 1) Bovine serum albumin (BSA) with molecular weight 67 kDa and net charge -18
at pH 7, 2) and Lysozymes (LYS), with molecular weight 14 kDa and net charge +7 at pH 7

143

.

They used three different initial loaded amounts of BSA and LYS; 200, 400, 600 μg, and
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expressed the loading efficiency as percentage of the loaded protein after washing. The results
showed that 60-80% of protein is loaded in the nanotubes regardless of the initial loading, see
Figure 2.14. Their release profile demonstrated that release kinetics can be also controlled by
varying nanotubes diameter and length 143.

Table 2.4, summarizes some of the ongoing efforts that are being exerted to study drug
loading and release kinetics for TiO2 nanoarchitectural reservoirs. Studies included are reporting
a wide range of therapeutics for different biomedical applications, such as anti-inflammatory,
antibacterial, anticancer and immunosuppressants. Factors, which affect drug delivery
functionality, including nanotubes morphology, dimensions (diameter and length), surface
chemistry, loaded drug properties, hydrophilicity …etc are described.

Figure 2.14: Loading efficiency of BSA and LYS at different initial loaded amounts 143.

Table 2.4: Summary of using TiO2 nanotubes for delivering selected therapeutics 146.

Main Target

Therapeutic loaded

Additional features

Ref

Antibacterial

Vancomycin

In-vivo studies

149

Penicillin/streptomycin

Loaded using simulated body fluid

150

Gentamicin

Osseointegrating

148
151

Cefuroxime
Silver nanoparticles

Osseointegrating/in-vivo studies

152

Zinc ions

Osseointegrating & anti-inflammation

153

40

Antimicrobial peptide

Also

hhc-36

bacteria

targets

antibiotic-resistant

155

Enrofloxacin

Anti-inflammatory

154

Ibuprofen

Osseointegrating/mechanical stability

156

studies
157

Indometacin
Indometacin

loaded

and Antibacterial and osseointegrating

157

chitosan/poly(lactic-co-glycolic
acid) coated
Naproxen
Dexamethasone

Loading

using

simulated

body

fluid/osseointegrating
Antifungal

158
159

Itraconazole
160

Osseointegrating

Gelatin stabilized gold- NPs
161

Bone morphogenetic- protein-2
(BMP2)
Pamidronic acids

Treatment of osteoporosis and Paget’s

162

disease
Pre-synthesized- hydroxyapatite

163

Strontium

164

Bisphosphonates (BPs)

Study on Ti-6Al-4V alloy surface/ In-

165

vivo investigations
166

C-terminal (connective- tissue
growth factor)- fragment

167

Doxorubicin

Anticancer

Selenium

Antibacterial and osseointegrating

169

Paclitaxel
Cisplatin

168

Osseointegrating

170

41

Immunosupressant

Sirolimus

Study on vascular smooth muscle cells

171

Neurotransmitters

Dopamine

Implantable drug delivery system for

172

brain conditions

Furthermore, many techniques were investigated to enhance drug loading and release rates
from TiO2 nanotubes. These are diagrammatically represented in Figure 2.15 and included for
example, (A) precise control over length and diameter, (B) surface chemistry, (C) using plasma
polymerization for tuning pore opening, (D) applying degradable polymeric coating on pore
surface, (E-F) loading with drug nanocarriers that may be used for multiple drug delivery as
well, (G-I) triggering drug release using external field, such as, magnetic field, temperature,
radiofrequency and ultrasound 146.

Figure 2.15: Strategies for enhancing drug release from TiO2 nanotubes (visualized using one
nanotube) 146.
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Chapter 3: Materials and Methods
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Chapter 3: Materials and Methods
3.1. Materials and Supplies
Titanium metal foils with thickness 0.25 mm and purity 99.95% were purchased from
Alfa Aesar, USA. Ti-45Nb alloy sheets with 45 wt% Nb and thickness of 2.5 mm were
purchased from Allegheny Technologies, Japan. Ti-17Nb-6Ta of thickness 0.3 mm were
received as prepared by Department of Materials Science and Engineering, Egypt-Japan
University of Science and Technology (E-JUST), Egypt, which was prepared by arch-heating
in argon gas (high purity) atmosphere. It was then homogenized at 1000 o C for 7.2 ks in same
atmosphere. Subsequently, samples underwent cold-rolling by 90% thickness reduction (CR).
Ammonium fluoride (ACS reagent, ≥ 98.0%), Formamide (purum, ≥ 98.0% (T)) and
Glycerol (ACS reagent, ≥ 99.5%) were purchased from Sigma Aldrich, USA. Ethylene Glycol
(Pure P.A.) was purchased from Lab-Scan analytical sciences, Poland, while Ammonium
Sulphate (Ex-Pure) was purchased from Oxford Laboratory, India. Hydrochloric acid (35-38%)
was purchased from Alpha Chemika, India. Sulphuric acid (98%), phosphoric acid (98%) and
perchloric acid (70% AR) were purchased from S D Fine-Chem Limited, India.
2’- Deoxyadenosine drug (99%) and phosphate-buffered saline (PBS, 1X), sterile liquid
were purchased from Alfa Aesar, Germany.

3.2. Potentiostatic Anodization
Anodization technique was used to fabricate arrays of Titanium and Titanium alloy
nanoarchitecture. Prior to the anodization process, Ti and Ti-alloys sheets were cleaned
ultrasonically in acetone then ethanol then distilled water. Platinum foil was washed in dilute
HCl then distilled water. The anodization electrochemical setup is built up from counter
electrode (platinum foil or graphite rod was used) and a working electrode of the substrate
material of interest (cleaned Ti and Ti- alloy sheets). Electrodes were immersed in different
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fluoride containing electrolytes in room temperature. Mixtures of different aqueous and organic
electrolytes that were used are summarized in Table 3.1 below.

Table 3.1: Summary of the anodization process conditions used for different substrates and/or to obtain
different morphology of nanoarchitectures

Electrolyte Code*

Electrolyte composition

Voltage/V Time/hour

PD1

0.2 M NH4F and 0.1 M H3PO4 , then complete 20

1.5

to final volume of 50 ml with distilled Water
FP2

0.2 M NH4F + 3 vol % H2O + 0.1 M H3PO4, 30

1.5

then complete to final volume of 50 ml with
formamide
FG3

0.35 M NH4F + 5 vol % H2O + 20 vol% 50

3

formamide, then complete to final volume of 50

2

ml with glycerol
AD4

0.11 M NH4F + 1 M (NH4)2SO4, then complete 40

2

to final volume of 50 ml with distilled water
*Electrolyte code: (Two main electrolyte components plus a serial numerical value)

Constant voltage between the counter and the working electrodes was applied using
E3641A key sight DC power supply for predetermined amount of time. Voltage and time
differed with the electrolyte used and are also summarized in Table 4.1. After anodization,
samples from aqueous electrolytes were ultrasonicated in distilled water, while those from
organic electrolytes were sonicated in acetone. Sample were afterward left to dry in air. Figure
3.1 demonstrates the setup used for this experiment and described above.
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Figure 3.1: The two-electrode potentiostatic anodization setup.

3.3. Surface Polishing
In attempt to enhance nanoarchitecture morphology and avoid the effect of surface oxide
layer on final structure, different surface polishing techniques were tried:

3.3.1. Mechanical Polishing
Mechanical polishing was done either manually or automatically. For manual polishing,
samples were fixed manually on a smooth surface and gently rubbed with grinding paper (600
grit/inch2). For automated mechanical polishing, samples were fixed on a metallic stage using
heated wax. Samples were exposed to grinding wheel with 600, 800 and 1200 grit/inch2 silicon
carbide papers, respectively and then treated with alumina of 0.5 µm. After polishing, samples
were detached from the metallic stopper by immersion in acetone under ultrasonication.
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3.3.2. Electrochemical Polishing
System used for electrochemical etching is the same as described previously in
potentiostatic anodization sector and demonstrated in Figure 4.1. However, the difference
between the two setups would be in the used electrolyte solution, voltage and time. Two different
systems were explored for electrochemical etching of desired samples.
System #1: Electrolyte of 30 vol. % H3PO4 and 70 vol. % ethyl alcohol is used. Solution
is stirred using heating magnetic stirrer, AREC at 500 rpm. The electrochemical setup is
surrounded by ice for temperature adjustment to 0 o C. Potential of 60 V is applied for 20
minutes.

System #2: Electrolyte of 20 vol. % HClO4 and 80 vol. % acetic acid (C2H4O2) at room
temperature is used. Potential of 35 V is applied for 4 minutes.

3.3.3. Chemical polishing

Chemical etching was done using etching system of hydrofluoric (HF) and nitric acid
(HNO3). Prepared etching solution consisted of 5 vol.% HF, 15 vol% HNO3, 80 vol.% distilled
water. Samples were immersed in the etching solution for 10-15 minutes. After removal, it was
cleaned with distilled water under unltrasonication for 1 minute.

3.4. Morphological characterization
Images were obtained for morphological characterization of Ti and Ti-alloys samples
fabricated and treated with different conditions, using Field Emission Scanning Electron
microscope. FESEM, Leo Supra 55 – Zeiss Inc., operated at 9.00 kV, was used to capture these
images. Images were used to detect the success of nanoarchitecture fabrication, measuring
dimensions, and study the effect of surface treatment prior and after anodization. FESEM was
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also used to study cell proliferation on different samples morphology as will be explained in a
later section. Finally, it was used to detect the accumulation of drug on sample surfaces post drug
loading experiment.
Only samples upon which is attached the cell culture are gold-sputtered before imaging to
enhance conductivity for better imaging. Otherwise, all samples were imaged as is.

3.5. Thermal Annealing
As required, as-anodized samples were thermally annealed in a furnace for a prespecified time. They were subjected to a temperature of 450 oC in air, with ramping heating rate
of 1 o C/min. Samples were annealed either prior to some characterization techniques, including
XRD, second run for the nanoindentation and number of FESEM-characterized samples, or as
surface treatment for controlling surface oxide layer. Steady temperature of 450 oC was
maintained for time interval of 2, 3 or 4 hours according to the purpose of the treatment. Furnace
used was Lindberg/Blue MTM Tube furnace, Thermo scientific, as shown in Figure 3.2.

Figure 3.2: Lindberg/Blue MTM Tube furnace, Thermo scientific, used in samples annealing.
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3.6. Structural and Compositional Characterization
Four different techniques were used to identify and confirm structure and/or composition of
fabricated NTs layer on Ti-17Nb-6Ta alloy. These techniques included:
-

XRD diffractometer (D8, Brucker) with a copper tube of 1.54Å wavelength.

-

High Performance Raman Analyzer (ProRaman-L) with an excitation laser beam,
wavelength of 532 nm.

-

Energy Dispersive X-ray Spectroscopy (EDX) detector equipped on FESEM, Leo Supra
55 – Zeiss Inc.

-

X-ray Photoelectron Spectroscopy (XPS) on a Thermo Scientific K-alpha XPS with an Al
anode. Spectra charged at 532 eV reference to O 1s.

3.7. Mechanical Characterization
Young’s Modulus and Hardness of the samples were measured before and after annealing
(at 450 o C for 3 hours). Tests were done using Nano Indenter XP, MTS with berkovitch tip (20
nm) creating 6 X 6 array of indentations, separated by 150 µm. Nanoindentation was done with
CSM Tip Calibration mode, strain 0.05 S-1, depth 3000 nm and strain rate 10 nm/sec. FESEM
was used to image the indentation projected contact area caused by the Berkovich tip.

3.8. Assessment of Nanoarchitectures’ Biological Response
For biological assessment vascular endothelial cells were extracted from mice umbilical
cords and cultured in-vitro. They were used for cytotoxicity measurements, cells adhesion and
proliferation on NTs. These tests were conducted at the holding company for biological products
and vaccines (VACSERA) and described as follows:
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3.8.1. Cytotoxicity Measurements
Cytotoxicity was assessed for Ti-17Nb-6Ta sheets as received, with Homo-NTs and
Hetero-NTs structures using MTT assay.

3.8.1.1. Sample Preparation

-

Samples were incubated in shaker incubator at temperature of 37 oC in culture media
overnight.

-

Samples’ extracts were collected after incubation.

-

Extracts were diluted serially to study cytotoxicity with MTT assay as will be described
as follows.

3.8.1.2. MTT Kit

-

MTT kit is based on reductive coloring reagent to detect mitochondrial dehydrogenase in
living cells. MTT in this assay is reduced by NADH to purple formazan.

-

Needles shaped crystals colored in purple are formed by MTT formazan due to its water
insolubility.

-

To solubilize these crystal, organic solvent is used. This allowed measurement of
absorbance to quantify cells viability.

3.8.1.3. MTT Assay:

1- Vascular endothelial cells were grown in culture media as monolayer. Media is
supplemented with fetal bovine serum, inactivated, 10%.
2- Cells were plated in 96-well tissue culture plate with 104 /well. They were incubated at
temperature 37 oC with 5% CO2 in a humidified incubator for 24 hours to allow cells
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attachment to the plate before adding samples extract. This step is excluded for blank
wells, which is used with no cells.
3- Different dilutions from samples extracts were added for testing cytotoxicity, except for
cell control wells. For each concentration, eight replicates were prepared, as shown in
plate design in Table 3.2 below.

Table 3.2: Plate design used for cytotoxicity MTT assay of different nanoarchitectures versus as received
substrate material.

Blank

Cell

Homo-NTs

Hetero-NTs

12

Alloy substrate

Control

A

0

-1

-2

0

-1

-2

0

-1

-2

B

0

-1

-2

0

-1

-2

0

-1

-2

C

0

-1

-2

0

-1

-2

0

-1

-2

D

0

-1

-2

0

-1

-2

0

-1

-2

E

0

-1

-2

0

-1

-2

0

-1

-2

F

0

-1

-2

0

-1

-2

0

-1

-2

G

0

-1

-2

0

-1

-2

0

-1

-2

H

0

-1

-2

0

-1

-2

0

-1

-2

4- Cells were cultured with the added samples extracts for 48 hours at temperature 37 oC
with 5% CO2.
5- After 48 hours, attached viable cells were separated by discarding culture media through
decantation. Discard media contained both samples extracts and dead cells.
6- Plate is afterward washed twice, using PBS (pre-warmed).
7- MTT reagent of 40 μl was added to each well including negative control wells and blank.
8- After adding MTT, plates were incubated for 4 hours in the dark to allow for the
reductive effect of mitochondrial dehydrogenase from viable cells to take place on MTT
reagent. Accordingly, MTT will change into purple needles of Formazan.
9- Purple needles of Formazan were solubilized by 150 μl DMSO, added to each well.
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10- To determine concentration in different well, absorbance was measured with microplate
reader (ROBONIK TM P2000 Eliza plate reader) at 570 nm.

Figure 3.3: Diagrammatic representation of MTT assay steps 168.

3.8.2. Cell Proliferation Assay
The following assays were conducted to study vascular endothelial cells proliferation on
different nanoarchitecture morphologies versus as received smooth Ti-17Nb-6Ta surface.
Endothelial cells were plated on the three Ti-alloy samples (As received, Homo-NTs, HeteroNTs) with cell densities of 5000 /cm2. Cells were incubated at 37

o

C with 5% CO2 and 70%

humidity for 24 hours. Afterwards, non-adherent cells were washed away using phosphate buffer
saline (PBS), to only leave adherent cells on surface of Ti- alloy samples.
Cell growth was analyzed after plating by counting adherent cells at days 1, 3 and 7. Analysis
was done by MTT viability assay (described earlier), Tryptan blue viability assay and imaging
under FESEM as described below:
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3.8.2.1. Tryptan Blue Viability
1- The cells monolayer was detached by trypsinization with Trypsin/EDTA (Ethylene
Diamine Tetraacetic Acid) solution (0.25%). Detached cells were re-suspended in fresh
medium that contains fresh bovine serum.
2- 100 µl of re-suspended cells were mixed with equal amount of tryptan blue (dilution
factor = 2) by gentle pipetting.
3- Hemocytometer and cover slip (shown in Figure 3.4) were thoroughly cleansed using
70% ethanol, before sliding the cover over the chamber.
4- 10 µl of cells suspension were added to both chambers of the hemocytometer and
inverted microscope was used to examine cell viability.
5- Bright non stained cells indicated viable cells, while blue stained ones indicated dead
cells. Both types of cells were counted under the microscope to calculate percentage of
cells viability.

Figure 3.4: Diagrammatic representation of hemocytometer used in Trypan blue assay 169.

3.8.2.2. Cell Imaging by FESEM
Endothelial cells were cultured on the as anodized samples for 3 days. Afterwards,
fixation of proliferated cells was done using gluteraldehyde, diluted with PBS. Samples surface
were gold-sputtered at 20 mA for 1 minute, using SEM coating unit E5000, Polaron Equipment
Limited. Samples were imaged using FESEM, Leo Supra 55 – Zeiss Inc., operated at 5.00 kV.
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3.9. Study of Nanoarchitecture as Potential Drug Carrier
3.9.1. Drug Loading
Both Homo-NTs and Hetero-NTs were studied as potential drug reservoirs for the
application of drug eluting stents (DES). Amount of loaded drug were compared between the
two systems to determine the more favorable platform. Triplicates were prepared and examined
for each platform to ensure reproducibility. Hydrophilic 2'-deoxyadenosine was used as the
cytotoxic drug molecule.

Steps for quantifying the percentage of drug loaded are described below:

1- For each sample, known concentration of the drug solution was prepared as 1 mg 2'deoxyadenosine per 1 ml distilled water in a 10 ml beaker (applying sink conditions).
2- Solution was stirred on magnetic stirrer (AREC) at 500 rpm for 2 minutes till complete
solubility.
3- One side of the as anodized cleaned samples were covered by an insulating material to
ensure drug loading into one side of the Ti-based anodized sheets.
4- Samples of 1 cm2 were immersed in the prepared solution and left for 36 hours without
stirring.
5- After the 36 hours, samples were removed from the drug solution and left to dry in air for
12 hours.
6- Insulating material was removed from the samples.
7- Each of the samples loaded with drug was immersed in a 10 ml beaker, containing 10 ml
PBS under magnetic stirring for 3 minutes at 700 rpm.
8- 1 ml of the PBS were withdrawn from the beaker using a pipette and its absorbance was
measured using CARY 500 scan, UV-Vis-NIR spectrophotometer at 260 nm.
9- For calculating the unknown concentration of drug released into the PBS, calibration
curve presented in Figure 3.5 was used. For preparing the calibration curve, serial
dilutions of known concentrations of the drug in distilled water were prepared and their
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absorbances were measured at 260 nm. Absorbance was plotted versus concentration
with setting trend line interception to zero.

Absorbance (amu) at 260 nm

Calibration Curve
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Figure 3.5: Calibration curve of 2'-deoxyadenosine in distilled water.

3.9.2. Drug Release Computational Study
Drug release profile from NTs was theoretically predicted using computational simulation. The
model was built using COMSOL Multiphysics ® 4.1 modeling software. To simulate the
kinetics of drug release from the NTs, “Transport of diluted species” module was used, with
Fick’s law equation governing the drug motion. Boundary conditions stated that flux outside the
boundaries of the NTs and the tissue is equal to zero.
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Chapter 4: Results and Discussion
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Chapter 4: Results and Discussion
Reference to the challenges currently facing drug eluting stents, which were discussed
earlier in chapter 1, the need for surface optimization of stent materials is considered crucial.
Efficient surface composition and morphology should allow controlled endothelial tissue healing
to avoid late thrombosis. On the other side, it should offer an ability to act as a drug carrier for
local drug delivery to avoid neointimal hyperplasia and vessel restenosis. This chapter covers the
results and discussion of the work undertaken to fabricate a nanoarchitectured system that shall
enhance tissue proliferation and can possibly act as drug reservoir.

4.1. Fabrication of Highly Ordered Arrays of Ti and Ti-Alloys
Nanoarchitecture
As discussed in chapter 2, few attempts were conducted to study the use of nano-surface
morphology for the use in drug eluting stents. However, reported results studied
nanoarchitectures fabricated from a material coated on the main stent substrate material. This is
done for two main reasons: 1- due to the sensitivity of the application to the material mechanical
properties. Stent material needs fine adjustment and tradeoff between mechanical properties
affecting the stent flexibility and strength that was not offered by the coating material alone. 2The coating was used as a biocompatible insulator between the vessel tissue and stent substrate
material that can possibly release cytotoxic metal traces. Nevertheless, self-grown
nanoarchitectures from the stent substrate can potentially be of greater benefit than different
coating-substrate materials. This shall reduce the number of processing steps required for
material coating and prior treatment to enhance adhesion. Self-grown layer would better avoid
stresses gradient and allow for better stronger bond.
In an attempt to present this self-grown system, fabrication of nanoarchitectures on Ti17Nb-6Ta alloy was investigated. Ti-17Nb-6Ta alloy is a potential material for self-expandable
stent that is meeting the biocompatibility and mechanical properties required for such
application. Their mechanical properties are comparable to Nitinol, which is currently the most
widely used material for self-exandable stents. Ti-17Nb-6Ta alloy has a Young’s modulus of 68
GPa, ultimate tensile strength (UTS) of 700-1050 MPa, Elongation of 10-30% and corrosion
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resistance of -44.1 Ecorr (mV). Furthermore, the tantalum content can possibly enhance radioopacity and stent visibility during PCTA due to its relatively high density. To fabricate ordered
morphology of nanoarchitectures on Ti-17Nb-6Ta ternary alloy, Ti pure and Ti-Nb binary alloys
were first investigated for optimization.

4.1.1. Pure Ti as Nanoarchitecture Substrate
Both aqueous and organic electrolytes for anodization setup were investigated. For
aqueous conditions, electrolyte PD1 from Table 3.1 was used. While for organic conditions,
electrolytes FP2 and FG3 were used. Figure 4.1 shows FESEM images for the as-anodized
nanotubes arrays. Aqueous electrolyte resulted in the formation of nanotubes (NTs) that are
distributed over the entire substrate. The NTs diameter varied widely along the layer (from 70 to
100 nm). However, outer diameter was observed to be irregular in structure with circumferential
serration and ridges, which is common with aqueous electrolytes. Hence, organic electrolytes
were investigated to optimize the NTs morphology, including alignment, dimensions and wall
regularity.

Figure 4.1.: Top view FESEM images of as-fabricated TiO2 NTs anodized in aqueous electrolyte at (A)
higher and (B) lower magnification.
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Regarding the use of organic electrolyte, first, formamide-based electrolyte (FP2) was
used. As shown in Figure 4.2. (A) and (B), the NTs structure was observed to be more defined.
NT diameter became more uniform (110 ± 10 nm). However, circumferential serration is still
observed. Furthermore, nanotubes are slightly bent inwards forming nanoscaled islands,
distributed along the substrate. Reducing the formamide content was followed for glyceol-based
electrolyte (FG3). It can be seen in Figure 4.2 (C) and (D) that NTs were significantly enhanced
towards more vertical alignment and smoother surface.

Figure 4.2.: Top view FESEM images of as-fabricated TiO2 NTs in formamide based electrolytes at (A)
lower and (B) higher magnification, and glycerol based electrolytes (C) lower and (D) higher
magnification.
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4.1.2. Ti-45Nb Alloy as Nanoarchitecture Substrate
Aqueous and organic electrolytes were explored for the anodization process of Ti-Nb
alloy to study the effect of electrolyte type on surface morphology. For aqueous-based
electrolytes, AD4 electrolyte was used at 40 V for 2 hours. It is evident from the FESEM images
of Figure 4.3 that vertically aligned nanotubes were successfully fabricated.

Figure 4.3.: FESEM images of as-fabricated NTs of Ti-45Nb obtained in aqueous (AD4) electrolye. (A)
and (B) are top views of the NTs at high and low magnification, respectively, showing NTs
heterogeneous dimensions and well distribution. (C) Side view of the NTs from imaging the sample at 90
degrees, showing the circumferential serration. (D) Side view of the NTs layer through imaging a
detached area, showing the NTs base and the layer total length.
60

Although the NTs are more defined, they still have circumferential serrations. It was also
observed that the NTs are well-distributed over the substrate with heterogeneous dimensions
within the same layer. NTs inner diameter varied widely between 75 and 145 nm, while the NTs
wall thickness ranged between 5 and 20 nm. The measured thickness of the NTs layer (as shown
in Figure 4.3 (D)) was found to be of average 5 µm despite of observed irregularity.
As described earlier, the NTs morphology was significantly enhanced with glycerolbased relative to formamide-based electrolytes in case of pure Ti. Accordingly, Ti-45Nb sheets
were anodized using FG3 electrolyte. When as-anodized samples were imaged under FESEM,
thick oxide layer was observed covering the NTs layer, which can negatively affect the NTs
functionality for the specified application. As shown in Figure 4.4 (B), well-defined NTs can be
seen beneath the oxide layer. Anodized samples were therefore further cleansed for longer
amount of time. They were ultrasonicated in acetone for 30 minutes and imaged again.

Figure 4.4: Top view FESEM images of as-anodized Ti-45Nb sheets in FG3 electrolyte. (A) Thick porous
oxide layer formed on the surface of the NTs and (B) arrow points to the well-defined NTs beneath the
oxide layer.
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It can be clearly seen from Figure 4.5 that sonication for long duration successfully
removed the undesired oxide layer without compromising the nanoarchitectured layer. Highly
ordered vertically oriented assemblies of nanotubes were revealed. They appear as closely
packed NTs with almost fused walls at the surface between adjacent NTs. They are assembled
into honey-comb like islands separated by grooves. It can be observed that NTs walls are highly
uniform and free from circumferential serration.

Figure 4.5: FESEM images of Ti-45Nb honey-comb like nanoarchitectures, fabricated using glycerolbased electrolytes. (A) and (B) top view images of low and high magnification, respectively, and (c) side
view from detached area after surface scratching.
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Furthermore and most importantly for the intended application; the NTs are
homogeneous in structure and dimension. Measured inner diameter is of average 90 ± 10 nm and
fused walls thickness of 11 ± 2 nm. Detached area from the NTs layer was imaged showing the
layer side view in Figure 4.5 (C). It showed long highly uniform vertically aligned NTs with
average length of 14 µm. It is evident from the figure that dimension of the tubular structure is
nearly uniform throughout the tubes’ length.

4.1.3. Ti-17Nb-6Ta as Nanoarchitecture Substrate
Based on the extremely promising results obtained from using FG3 electrolyte with Ti-45Nb
alloy, it was studied with the Ti-Nb-Ta alloy sheets to reproduce such ordered nanoarchitectural
structure from Figure 4.5. As received samples were anodized using the same conditions of FG3
electrolyte mentioned in Table 4.1. First outcome resulted in the morphology observed in Figure
4.6. It showed highly rough layer that is totally covering the substrate. Evidence of NTs
assembly were clear from Figure 4.6 (B) and (C) where NTs were seen either detached or
underneath the rough surface. However, this structure can completely hinder the functionality of
the nanoarchitecture and it is essential to remove it. Cleaning attempts using ultrasonication for
long duration failed to overcome this problem and other techniques needed to be explored.
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Figure 4.6: FESEM images of (A) high rough surface on as anodized samples, (B) NTs beneath the layer,
and (C) detached NTs assembly.

Referring back to the thermal history of the received Ti-17Nb-6Ta alloy sheets, it was
found that they were oxidized at high temperature of about 800 o C. This is sufficient to result in
a thick oxide layer prior to any electrochemical processing. As received samples were therefore
imaged prior to anodization to examine surface roughness and optimize accordingly. As shown
in Figure 4.7 highly rough surface was observed on Ti-17Nb-6Ta substrate. This rough structure
can most probably remain persistent after anodization and cause the observed rough layer
covering the nanotubes. Prior anodization processing was therefore essential to prepare the
sample for NTs fabrication. Accordingly, sample polishing prior to anodization was studied
through a sequence of different techniques with varying outcomes.
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Figure 4.7.: Top view of FESEM images for as received Ti-17Nb-6Ta alloy sheets prior to anodization, at
(A) lower and (B) higher magnification.

4.1.3.1 Mechanical Polishing
Manual polishing was first explored using grinding paper to gently polish the surface
manually prior to anodization. Samples were afterwards anodized using FG3 electrolyte
conditions. For as anodized samples, FESEM images showed improvement in surface
morphology. Highly rough surface was not observed anymore. However, it was replaced by
another morphology of oxide layer covering almost all the substrate surface. This layer can be
described as thick nanoporous oxide layer with NTs of thick walls appearing beneath, as shown
in Figure 4.8.
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Figure 4.8: Top view FESEM images for pre-polished anodized Ti-17Nb-6Ta sheets, showing
nanoporous oxide layer covering the underneath NTs at (A) low and (B) high magnification.

In attempt to avoid the build-up of the oxide layer, manual polishing was replaced by
automated mechanical polishing described in chapter 3. Samples were anodized post polishing
using FG3 electrolyte with the same conditions previously described. As shown in Figure 4.9
(A), it was found that density of thick nanoporous oxide layer from Figure 4.8 decreased
significantly. It showed larger pores diameter with thinner walls in between. Furthermore, NTs
appearing beneath the layer became more uniform and vertically oriented, as shown in Figure 4.9
(B). The anodized layer, including both oxide layer and underlying nanotubes, was removed by
ultrasonication in acetone for 30 minutes. Another step of anodization was performed on the
same sample in attempt to guide a more uniform assembly of nanotubes, using the same
electrolyte. As observed in Figure 4.9 (C), the less dense oxide layer appeared only in scattered
areas along the substrate surface after second anodization. And large areas of nanoarchitectures
started to be revealed. However, various morphologies of nanoarchitecture was observed in
different areas along the sample, as shown in Figure 4.9 (D). These non-uniform assemblies can
hinder the control over the intended outcome during application.
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Figure 4.9: Top view FESEM image of the two steps anodization of Ti-17Nb-6Ta sheets after automated
mechanical polishing. (A) and (B) shows the less dense nanoporous oxide layer covering the nanotubes at
higher and lower magnification respectively. Arrow on image (B) shows uniform vertically oriented NTs
beneath the oxide layer. (C) and (D) shows resulted structure from second anodization after removing the
as anodized layer from step one using ultrasonication. (C) Shows that larger area of NTs started to reveal
leaving the oxide layer with significant distance apart. (D) Covers different NTs morphology that was
observed along the same substrate.
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4.1.3.2. Electrochemical Polishing

In order to avoid surface abrasion, strains and contamination that can potentially be
caused by mechanical polishing, electrochemical polishing was explored to optimize preanodization surface treatment. Two electrochemical setups were studied as described in chapter
3, followed by samples anodization using FG3 electrolyte. System #1 that used phosphoric acid
at 30 vol. % was not successful in avoiding the oxide layer formation on the NTs surface. It can
be seen in Figure 4.10 that pre-treatment with system #1 resulted in uniform NTs with relatively
thick wall underlying a low-porosity oxide layer. The assemblies, however, showed islands-like
morphology, separated by grooves characteristic for FG3 electrolyte.

Figure 4.10: Top view FESEM images of as anodized Ti-17Nb-6Ta sheets after pre-anodization treatment
using system #1 electrochemical anodization. (A) higher magnification showing uniform, vertically
aligned nanotubes below the oxide layer. (B) lower magnification showing the island like assembly of
NTs covered with low-porosity oxide layer.
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Stronger acid (perchloric acid) was accordingly studied through system #2 for preanodization electrochemical treatment. More underlying NTs were revealed, as shown in Figure
4.11. NTs morphology was closer to the expected FG3 outcome with relatively thinner tubes
wall, high vertical alignment and uniformity. However, although oxide layer was found more
distant apart, it remained persistent with this polishing technique. Also, overall electropolished
area was found to be about only 20% of the whole substrate surface area. Furthermore, NTs layer
assembled on electropolished areas was easily detached with minimum stress. Hence, another
technique had to be explored for sample polishing.

Figure 4.11.: FESEM images of as-anodized Ti-17Nb-6Ta samples, post electrochemical polishing using
system #2. (A) Top view for relatively thin walled NTs close to the morphology produced by FG3
electrolyte. And it can also be seen to the right, oxide layer deposited on the surface. (B) Side view of
highly ordered nanotubes assembly, detached from the layer of almost 11 µm in length.

4.1.3.3. Chemical Etching

Pretreatment in chemically etching solution as described in chapter 3, revealed the best
results among the different explored polishing techniques. The very strong acid (HF) used
resulted in the most successful solution to remove the oxide layer built on NTs surface without
the need of external forces either mechanical or electrochemical. As seen in Figure 4.12, it only
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left randomly distributed debris revealing highly ordered NTs. Among the previously described
polishing techniques, chemical etching showed the best results. Results obtained from different
polishing treatments confirmed that substrate preparation and pre-anodization treatment directly
and greatly influence the final NTs morphology, uniformity and distribution.

Figure 4.12.: Top view FESEM image of as anodized Ti-17Nb-6Ta samples, post chemical etching. (A)
Lower magnification showing the relatively heterogeneous nanoarchitecture along the surface. (B) High
magnification at area of highly ordered, vertically oriented NTs with morphology and dimensions as
expected from FG3 electrolyte. (C) and (D) show the randomly distributed debris on as anodized NTs
surface.

70

4.1.3.4. Unprocessed Ti-17Nb-6Ta Alloy
Based on the previously reported findings, anodization was done for samples with no
thermal treatment history post preparation. After samples were cold rolled, they were directly
anodized in attempt to avoid the oxide layer formation without the need of sample polishing. As
expected, it is clear from Figure 4.13 that anodization using FG3 electrolyte conditions was
successful to fabricate highly ordered, vertically oriented NTs for Ti-17Nb-6Ta substrate.

Figure 4.13: FESEM images of as-anodized Ti-17Nb-6Ta with no thermal treatment history. (A) Low
magnification top view of the highly ordered, vertically oriented NTs packs, with dissimilar packs’
length, (B) high magnification top view of the ordered NTs showing NTs homogenous structure, (C) and
(D) side views of NTs detached layers, showing NTs bottom side at lower and higher magnification,
respectively.
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They can also be described as closely packed NTs assembled into honey-comb like
islands separated by grooves. Packed NTs appeared having fused walls at the surface. Side view
observed from detached layer or variation in packs length, showed highly defined NTs with
distinct, uniform walls and free from circumferential serration. Tubes diameter is observed to be
uniform along the length. As observed from bottom view of Figure 4.13 (C) and (D). It can be
safely called homogeneous NTs (Homo-NTs), and will be the first morphology of
nanoarchitecture proposed for the intended application. NTs dimensions were found to be of
average inner diameter 75 ± 5 nm and length of 12 µm. Dissimilar packs’ length of NTs is
observed in Figure 4.13 (A). It is potentially justified by different etching rates of Ti-17Nb-6Ta
alloy components by fluoride containing electrolyte reference to elements activity. This structure
of homogeneous NTs was studied for enhancing drug eluting stents by enhancing material
biological response and drug loading capacity as will be described in the following sections.

4.1.3.5. Variation in NTs Morphology for Biological Application

Aqueous electrolyte was studied for anodizing Ti-17Nb-6Ta with no thermal treatment
history. This was an attempt to reproduce heterogeneous structure observed with Ti-45Nb by
using aqueous electrolyte. Samples were anodized using AD4 electrolyte conditions and imaged
with FESEM. As seen in Figure 4.14, anodization was successful to produce vertically aligned
nanotubes, uniformly distributed on samples’ surface. The structure is referred to as
heterogeneous NTs (Hetero-NTs) since measurement of inner diameter and wall thickness varied
significantly. Tubes’ diameter ranged from 80 nm up to 190 nm along the same substrate. Wall
thickness varied within range of 6 nm up to 28 nm. However, the length of NTs layer was found
to be of average 12 µm. Heterogeneous NTs were fabricated to be studied in comparison with the
previously described homogeneous NTs for the intended application. With almost similar layer
length for the two morphology, this variable was excluded from the comparison. Effect of
surface morphology between Homo- and Hetero- NTs was studied for endothelial tissue
biological response and system capacity to load therapeutic agents for drug eluting stents.
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Figure 4.14: Top view FESEM images of as-anodized Ti-17Nb-6Ta sheets using aqueous AD4
electrolyte. (A) and (B) show the heterogeneous NTs dimensions at low and high magnification,
respectively.
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4.2. Structural and compositional Characterization
Composition and crystallinity of the as-fabricated Ti-17Nb-6Ta samples were first
examined using X-ray diffraction (XRD) and Raman spectroscopy on annealed sample at 450

o

C. Figure 4.15, evidently confirms the crystallization of the nanotubes in the anatase phase, with
appearance of peaks corresponding to (101), (103), (004), (112), (200), (105), (211), (213) and
(220) facets. These peaks are normally indicative of titania NTs anatase phase as reported in
literature

173–176

. However, absence or existence of the other alloy components, i.e. Nb and Ta,

cannot be confirmed nor denied from these results. It was reported that both Nb and Ta existence
with titania may not alter greatly nor postpone its phase transformation from amorphous to
177–179

anatase

. Results from Ti-xNb, Ti-xTa- xZr and Ti-xTa annealed samples at 450

o

C

revealed the same peaks’ positions reported with anatase phase of titania NTs. This indicates
possible overlapping of peaks from the three components 180–182.
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Figure 4.15: X-ray diffraction pattern of as-fabricated Ti-17Nb-6Ta NTs, annealed at 450 o C for 3 hours.
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Results from XRD was supported by Raman spectra, as shown in Figure 4.16. It
indicated the tetragonal vibration mode symmetries associated with anatase, of peaks
corresponding to Eg, Eg, B1g and A1g modes 174,175. However, slight shift and broadening of some
peaks may be indicative of presence of other elements in the crystal 183. Yet, no distinctive peaks
were revealed for Nb or Ta for confirmation. Accordingly, this could not be considered accurate
analysis for surface composition.

Figure 4.16: Raman spectrum of the fabricated Ti-17Nb-6Ta NTs, annealed at 450 o C for 3 hours.

More sensitive and accurate technique was, therefore, needed for confirming or denying
the formation of mixed oxides on the as anodized surface. The three alloying elements have
different activities towards etching and evidence was then needed to make sure the three
elements were retained during anodization and within the NTs. Accordingly, X-ray
Photoelectron Spectroscopy (XPS) was used, which results in fingerprint elemental analysis.
XPS is considered a powerful tool for identifying the surface components, chemical composition
and oxidation degrees. Spectra for as anodized Ti-17Nb-6Ta samples, indicated the presence of
Ti, Nb, Ta, and O elements, and confirmed the formation of Ti-Nb-Ta mixed oxides, as
illustrated in Figure 4.17.
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Figure 4.17: XPS spectra of the (A) Ti 2p, (B) Nb 3d, (C) Ta 4f and (D) O 1s emission peaks for Ti17Nb-6Ta as-anodized formed nanotubes.

Figure 4.17 shows the XPS spectra for the alloy. Figure 4.17 (A) shows two peaks that can be
assigned to Ti 2p1/2 and Ti 2p3/2. The peaks are located at 464.6 eV and 458.7 eV with spin orbit
splitting (Δ) = 5.9 eV associated with Ti4+ (1). Figure 4.17 (B) revealed Nb3d doublet at 210.98
eV and 208.08 eV associated with Nb 3d3/2 and Nb 3d5/2. It showed spin orbit splitting (Δ) = 2.9
eV, confirming that signals correspond to Nb5+ (2). In Figure 4.17 (C), peaks appeared at 29.08
eV for Ta4f5/2 and 27.18 eV for Ta4f7/2. Spin orbit splitting (Δ) was found to be equal 1.9 eV
confirming presence of Ta5+. Finally, Figure 4.17 (D) shows Oxygen indicative peak O1s, with
only single peak is observed located at 530.98 eV.
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These results were supported by Energy dispersive X-ray spectroscopy (EDX) as a
qualitative elemental analysis technique. As observed from Figure 4.18, EDX showed that the
surface formed of NTs were composed of Ti, Nb, Ta and O. Overall composition was found to
be relatively consistent with the composition of the substrate forming alloy, yet Ta content is
slightly higher than expected. This, however, confirms that compositions of NTs depend upon
titanium alloy elemental composition.
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Figure 4.18: EDX peaks and composition of Ti-17Nb-6Ta-1O formed nanotubes, analysed within the
specified spectrum
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4.3. Nanomechanical Characterization
Not only that material mechanical properties are critical for drug eluting stents, but also
biological interaction with material surfaces is sensitive to mechanical properties at the interface.
Surface stiffness was found to significantly influence cells fate

57,184

.The mechanical properties

of the fabricated nanoarchitectures were measured using nanoindentation technique.
Nanoindentation tip was used to obtain Young’s modulus (a measure of stiffness) and hardness
values, before and after annealing. During loading and unloading, hysteresis loop was observed,
which indicated that NTs surface has elastic energy dissipation, as seen in Figure 4.19. It can be
observed from the curves below, that elastic recovery is higher for annealed sample (Figure 4.19
(B) and (D)) reference to their unannealed counterpart. Also, unloading slope of annealed
samples are found to be steeper indicating higher stiffness.

(A)

(C)

(B)

(D)

Figure 4.19: Average load-displacement curves from nanoindentation of (A), (B) Homo-NTs and (C), (D)
Hetero-NTS, before and after annealing respectively.
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From inspecting Figure 4.19, total depth of indentation is much smaller than the NTs
layer thickness (12 µm). Accordingly, insights on NTs plastic deformation behavior can be
gained without interference from substrate material. Young’s modulus and hardness average
values were calculated and compared for Homo-NTs and Hetero-NTs before and after annealing,
as shown in Figure 4.20. It was found that both Young’s modulus and hardness increase with
annealing for both Homo- and Hetero-NTs, which can be explained by phase transformation
upon annealing. For hardness, Homo-NTs were found to be superior. For Young’s modulus,
Homo-NTs showed lower values, which does not indicate inferiority within intended application.
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Figure 4.20: Young’s modulus and hardness values for Homo- and Hetero-NTs, before and after
annealing.

79

4.4. Influence of Nanoarchitecture Surface Morphology on Biological
Response
4.4.1. Cytotoxicity Measurements
As any biomaterial that will be in contact with biological components, assessment of the
material’s cytotoxicity is crucial to be considered in biomedical applications. This is a mandatory
step before considering any in-depth proliferation studies. For Ti-17Nb-6Ta alloy, samples were
assessed to ensure not only the safety of the alloy material, but also the effect of the used
electrolytes in nanotubes fabrication on materials biocompatibility.
As described in chapter 4, MTT assay was used to assess cytotoxicity for 3 samples’
surfaces: 1) Ti-17Nb-6Ta sheets as received, 2) with Homo-NTs and 3) Hetero-NTs structures.
Each sample’s extract were tested through 3 different dilutions, each repeated eight times for
results reproducibility. According to plate design illustrated in chapter 3, microplate reader
absorbance results were retrieved as described in Table, 4.1 below. Also readings for blank and
cell control were recorded for percentage of cells viability calculations.

Table 4.1: Absorbance results of MTT assay for Ti-17Nb-6Ta samples; as received substrate and the two
different nanotubes morphologies fabricated and reported earlier.

A
B
C
D
E
F
G
H

Blank
1
0.006
0.007
0.004
0.006
0.005
0.006
0.003
0.006

C.
control
2
0.421
0.422
0.423
0.424
0.421
0.423
0.421
0.423

Homo-NTs
3
4
0.422 0.423
0.424 0.421
0.425 0.425
0.423 0.424
0.42 0.422
0.421 0.423
0.421
0.42
0.424 0.422

5
0.42
0.422
0.423
0.421
0.424
0.423
0.422
0.425

Hetero-NTs
6
7
0.423 0.422
0.424 0.421
0.42 0.424
0.422 0.424
0.423 0.421
0.423 0.421
0.423 0.422
0.421 0.423

8
0.423
0.422
0.423
0.422
0.424
0.422
0.423
0.421

Alloy substrate
9
10
11
0.421 0.424 0.423
0.42 0.421 0.422
0.421 0.423 0.422
0.424 0.421 0.423
0.424 0.422 0.424
0.421 0.422 0.421
0.421
0.42 0.421
0.421 0.424 0.423
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From absorbance reported data, percentage of cell viability for different samples’ extract
were calculated using the following equation and presented in Figure 4.21:

𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑟𝑎𝑡𝑒 % =

𝐴 𝑠𝑎𝑚𝑝𝑙𝑒−𝐴b
𝐴c−𝐴b

× 100

(4.1)

where Ac is the negative control and Ab is blank.

Figure 4.21. Illustrates the percentage of cells survival rate or cell viability for 1) Ti17Nb-6Ta sheets with as anodized Homo-NTs, 2) with Hetero-NTs structures, and 3) as received
substrate material measured by MTT assay. Data present 3 different dilutions for each sample’s
extract (0, -1, -2). It can be clearly seen that cells survival rate is about 100% for all samples and
different dilutions. This indicates almost no cytotoxicity at all for the substrate alloy material
used. It is also clear that results from NTs fabricated using different electrolytes (FG3 for HomoNTs and AD4 for Hetero-NTs) are as promising as the substrate material. This exclude any
possible cytotoxicity from electrolyte after sample cleaning post anodization.
These results are highly consistent with the biocompatibility and hemocomatability
reports in literature for Titanium and Titanium alloys 185,186.Such high degree of biocompatibility
is attributed to the ability of Ti-based alloys to form a stable oxide layer in most environments.
Furthermore, the thicker and more stable oxide layer, the better is the material bioactivity. This
has driven earlier attempts to increase biocompatibility and activity of material surfaces by
increasing oxide layer through anodization techniques 187-190.
For Drug eluting stents (DES) application, material stability and cytotoxicity are
considered crucial. The use of materials with any inflammatory effect can cause local tissue
sensitization, which can directly affect the healing process as well as the local thrombogenicity.
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In this work, NTs are proposed as platform for enhancing endothelial tissue regeneration
as well as to act as drug carriers. Accordingly, it is proposed to replace polymer coating on stents
struts, which leaves Ti-17Nb-6Ta substrate and NTs in direct contact with biological
components. This confirms the significance of % cells viability results obtained for the material
under study. From results reported in Figure 4.21, Ti-17Nb-6Ta can be potential material for
DES and can be considered for further in-depth investigation regarding proliferation studies.

% Cell viability
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98
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Figure 4.21: Mean values of percentage of cell viability for 1) Ti-17Nb-6Ta sheets with Homo-NTs, 2)
with Hetero-NTs structures and as received substrate. It is illustrated for each sample, values for three
different dilutions (0, -1, -2) of tested samples extracts.
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4.4.2. Activation of Endothelial Cells Growth on Ti-based Nanoarchitectures
Ultimate vascular conditions post percutaneous coronary angioplasty and stenting can be
described as fast controlled healing of endothelial cells. Endothelial cells regeneration at site of
injury would directly enhance patient prognosis and stenting outcomes. As the inner most lining
of the blood vessel, intact endothelial cells can prevent thrombus formation as well as avoid
neointimal hyperplasia. This would allow the need of lower doses of local cytotoxic drugs and
more importantly would decrease the duration of oral antiplatelet therapy required for the
patients.
As reported in chapter 2, nanoarchitectures supported the migration, adhesion and
proliferation of mesenchymal stem cells and endothelial cells. Different biological response was
studied and reported for samples of different NTs diameters 109, 139-141. In this work, the influence
of nanoarchitecture of as anodized Ti-17Nb-6Ta was studied versus smooth substrate surface of
the same material. Furthermore, the effect of another morphology related factor on cells
activation was investigated. This factor involved NTs dimensional homogeneity, by comparing
endothelial cells proliferation on Homo-NTs prepared by FG3 electrolyte conditions versus
Hetero-NTs prepared by AD4 electrolyte conditions.
This section reports studies of endothelial cells proliferation for 3 types of Ti-17Nb-6Ta
samples; 1) Smooth surface of as received alloy, 2) Homo-NTs and 3) Hetero-NTs. Proliferation
results were reported using 3 different studies:
-

Cell counts from Tryptan blue cells viability assay.

-

MTT cells viability assay using absorbance data as an indicative measure.

-

Visual observation by imaging under FESEM.

4.4.2.1. Trypan Blue Cells Viability Assay
The three different samples underwent tryptan blue viability assay, and for each sample
both dead and viable cells were counted under the microscope at specific time intervals of 1, 3
and 7 days. Counted viable cells of the three samples are illustrated and compared below at the
specified time intervals, as shown in Figure 4.22.
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It is evident from the graphical representation in Figure 4.22 that nanoarchitectures
directed better proliferation of endothelial cells than smooth surface of material substrate at the
three studied time intervals. This directly supports the proposed hypothesis that surface
modification of drug eluting stents with nanotopography would guide faster endothelial healing.
Therefore, replacing the DES polymeric coating with NTs can be of great potential towards
better stenting outcome in terms of biological response. This shall not only spare the local
inflammation that may be caused by used polymer, but also promote endothelial tissue proper
healing.
Furthermore, the effect of changing surface topographies through differently anodized
samples were compared. Homo-NTs clearly showed higher number of counted cells than HeteroNTS, indicating better proliferation. This signifies the importance of NTs optimization in terms
of dimensional homogeneity, which should be considered for the applications involving tissue
regeneration. During endothelialization, nanoarchitectures mimic temporarily extracellular
matrix (ECM) guiding and nurturing cells growth

113, 191

. Superior outcome from Homo-NTs

may be attributed to better distribution of ions, proteins and nutrients required for the growth, as
well as more structured spatial guidance of cells to grow.
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Figure 4.22: Viable endothelial cells count on 1) Ti-17Nb-6Ta smooth surface 2) with Homo-NTs, 3)
with Hetero-NTs structures at different time intervals (1, 3 and 7 days)
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4.4.2.2. MTT Assay:
For confirming trypan blue assay results, MTT assay was conducted for the same 3 types
of samples of Ti-17Nb-6Ta; 1) Smooth surface of as received alloy, 2) Homo-NTs and 3)
Hetero-NTs. Absorbance of Formazan solutions was reported as a reflection of viable cells
concentration per sample. Reading were accordingly compared, as shown in Figure 4.23. Better
outcome with nanoarchitecture was confirmed versus smooth surface. Also, Homo-NTs showed
the same trend reported with trypan blue assay as the superior morphology for proliferation
among the three samples.
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0.15
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0.05

0

Day 1
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Figure 4.23: Formazan absorbance from MTT cell viability assay for: 1) Ti-17Nb-6Ta smooth surface 2)
with Homo-NTs, 3) with Hetero-NTs structures at different time intervals (1, 3 and 7 days)
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4.4.2.3. FESEM Imaging of Cells Proliferation
Endothelial cells were grown on the surface of Homo-NTs and Hetero-NTs for 3 days to
confirm the effect of dimensional homogeneity on cells’ proliferation. Cells were fixed and
imaged using FESEM, as shown in Figure 4.24. Cells morphology and degree of proliferation
shown in Figure 4.24, confirm the superiority of Homo-NTs in guiding endothelialization over
Hetero-NTs.
Images (A),(C) and (E) on the left side of Figure 4.24, represents cells’ growth on
Homo-NTs, where the island like structure of highly ordered nanotubes can be seen at the
highest magnification (E). While, images (B), (D) and (F) on the right side of the figure
illustrates cells on Hetero-NTs, and as well at highest magnification (F) NTs with different
diameters can be observed.
Elongated endothelial cells are predominantly seen on Homo-NTs. On the same
morphology cells are more distributed and almost forming network like structure. Also, cells
show more pronounced filopodia protrusions. This indicates better cells migration and
proliferation more on the homogeneous structure of NTs, which would directly results in higher
cells count as seen in the former assays. Cells cultured on Hetero-NTs, on the other hand,
showed more rounded structure, less spread on the surface and not yet crossing into a network.
This indicates potential of slower healing rates for Hetero-NTs in applications.
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Figure 4.24: Top view FESEM images of endothelial cells grown on NTs surfaces after 3 days.
(A), (C) and (E) are cells grown on Homo-NTs at different magnification. (B), (D) and (F) are
cells grown on Hetero-NTs at different magnification.
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4.5. Ti-based Nanoarchitectures as Drug Reservoir
4.5.1. Drug Loading
Work reported in this section was intended to evaluate the potential use of the fabricated
nanoarchitectures as drug reservoir. This is a critical feature for any material to be proposed as a
platform for DES surface modification. As polymer coatings replacement, Ti-based NTs are
intended to locally deliver any of drug classes used to avoid neointimal hyperplasia. The
proposed platform is intended to deliver the drug only into the vascular tissue side and not the
vessel lumen. Accordingly, anodized samples were tested for drug loading only on one side of
the sheet covered with the NTs layer, to avoid interference or duplication of results from the
other NTs layer.
Concentration of loaded drug in 1 cm2 NTs layer was calculated, using the calibration
curve described in chapter 3. This was done for both Homo-NTs and Hetero-NTs of 12 µm
length. Amount of loaded drugs were calculated and plotted, as shown in Figure 4.25.
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Figure 4.25: Comparison between drug loading capacity of Homo-NTs and Hetero-NTs.
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Results were compared between the two NTs morphologies to assess system superiority.
It is evident from Figure 4.25 that Homo-NTs drug loading capacity is almost double HeteroNTs. This can be explained by grooves found with Homo-NTs between islands of compact
nanotubes, see Figure 4.26. These grooves can reach width of up to 1 µm. Accordingly, they can
act as potential reservoir for higher amounts of drug causing this gap between both platforms. As
described, Homo-NTs showed more promising results for both biological response as well as
drug loading. Accordingly, it was further studied for its drug release profile using computational
analysis.

Figure 4.26: FESEM image, top view of Homo-NTs, showing grooves between compact NTs
islands
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4.5.2. Drug Release by Computational Simulation
In this work, a simulated model was used to examine and describe the release profile of
2’- deoxyadenosine from Homo-NTs. “Transport of diluted species” module was used for the
simulation. As concluded from previously reported biological response and drug loading for the
two NTs morphologies, results came in favour of Homo-NTs. Accordingly, release behaviour
was furthermore predicted for the practically loaded amount of drug from Homo-NTs. In order to
simulate the system, the physical model was first defined to identify model’s geometry, system
parameters, boundary’s conditions and equations that would govern the simulation.
Figure 4.27 facilitates the description of the system’s physical model. The figure shows a
cross section of the vessel at the healthy state (on the left) and after stenting (on the right). With
healthy vessels, wall tissue is still intact and demonstrating the three layers building the wall; 1)
innermost “Intima” (endothelium lining followed by connective tissue), 2) the middle layer
“Media” (composed of smooth muscles) and 3) The connective tissue of the outer layer
“Adventitia”. However, after stenting, metal struts are embedded into the intima with direct
contact with the connective tissue, while endothelium is almost damaged. Stent is taking the
shape of a ring, spanning the entire vessel circumference. Atherosclerotic plaque is
hypothetically considered to be totally removed during PTCA.
By magnifying at stent-tissue interface, the NTs delivery system is illustrated. Homo-NTs
are grown vertically on Ti-alloy substrate, which is embedded in the vessel wall tissue. Drug
release is intended to be in the direction of vessel wall only, hence not affected by the central
blood flow in the vessel lumen. Therefore, mass transport in the model was identified to be
dominated by diffusion and excluded both convection and migration. Accordingly, equation that
governed the drug motion was set to be of Fick’s law:
𝜕c𝑖
𝜕t

= Di . ∇2 ci

(4.2)

where for species i, Di = the diffusion coefficient (m2 /s), and ci = the concentration (mol /m3).
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Healthy Vessel

After Stent deployment

A) Vascular tissue in direct contact
with NTs.
B) NTs fabricated on the surface of
stent substrate.
C) Direction of drug elution from
NTs.
D) Stent struts (substrate material).
E) Blood flow inside vessel lumen.

Figure 4.27: Illustration of physical model representing the NTs drug delivery system into vessel’s tissue.
The Figure is just diagrammatic representation, not representing actual relative dimensions of the system
components.
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Drug release was assumed to be restricted to the surrounding tissue moving across the
connective tissue of Intima layer – as endothelium lining is damaged – and into the Media.
Boundary conditions were therefore described to restrict the flux within that system and indicate
that flux outside its boundaries is equal to zero (n. Ni = 0). Accordingly, the model geometry was
built as shown in Figure 4.28 with 2D spatial dimension, comprising the modeling domains
within the system boundaries; the NTs, Intima layer (excluded damaged endothelium and Media
layer.

Figure 4.28: 2D geometry of the modeling domains for drug release from NTs.

Simulation parameters were identified reference to the previously reported practical
results. Dimensions of Homo-NTs were about 75 nm in diameter and 12 µm in length, as
fabricated by FG3 electrolyte conditions. Initial drug concentration in the NTs was 0.001671
mol/m3, which was loaded within 36 hours in static conditions. Materials of the model domain
were identified according to their diffusion coefficient (Dc). For Intima, Dc is = 5.4 × 10
m2/sec and for Media Dc is = 5.0 × 10

-14

-12

m2/sec 192. This difference in D can directly affect the
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drug elution as diffusion coefficient can be the rate limiting step for mass transport across the
system. Diffusion coefficient of the drug in the NTs was calculated using the following equation
193

:
𝑀𝑡

√𝑀

𝑜

×2

=

𝐷𝑡

(4.3)

𝜋 ℎ2

where Mt is equal to the amount of drug released at time t, Mo is equal to the initial drug amount

and h is the layer thickness.

These values were retrieved from practical data measured for the same drug by Kang, et
al 138. Calculated value of drug diffusion coefficient was found to be = 2.5 × 10

-11

m2/sec. Using

the aforementioned parameters, time dependant study was designed for the drug release profile.
Concentration distribution of the drug was simulated as a function of time across the NTs and the
wall tissue (Intima and Media). Figure 4.29 shows drug concentration across the modeling
domains, using the 2D geometry and its 3D representation by axial symmetry at the end of the
simulation (3 days). Darkest red area represents the higher drug concentration, while darkest blue
represents the lower concentrations.
Time dependant estimation of drug released was used to plot drug concentration in NTs
over time. As seen in Figure 4.30, almost 100% of the initial drug amount was released after 3
days. For DES, this rate can be considered faster than required, reference to polymeric coating
drug release over duration of one month. This may need more control over the system by for
example any of the strategies mentioned in chapter 2, such as polymeric coatings over NTs
pores, using drug carriers or external fields 140.
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(A)

(B)

Figure 4.29: Drug concentration over the modeling domain with A) 2D and B) 3D geometry at
the end of simulation (3 days).
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Figure 4.30: Calculated drug concentration in the NTs over time

However, other factors may have resulted in such relatively fast rate other than the
inherent properties of the NTs system. This may include the initial amount of loaded drug. It is
assumed that drug loading may increase by increasing the initially added drug and the techniques
used for loading other than static solutions. This may not only increase the total amount of drug
released but also decrease the elution rate. Also, the nature of the drug is a critical factor in such
context. The tested drug (2’- deoxyadenosine) is hydrophilic with higher diffusion coefficient
than hydrophobic drugs used mainly in the market. Extending the measurement into hydrophobic
molecules with lower diffusivity may slow down the rate and sustain the release.
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Chapter 5: Conclusions and Future Perspective
Complications associated with drug eluting stents arise from its vulnerability to in-stent
thrombosis. This is directly attributed to late regeneration of endothelial cells, lining the blood
vessels, injured during mechanical perfusion of the vessel. Furthermore, undesired events can be
associated with potential hypersensitivity of local biological medium to stent polymeric coating.
In this thesis, a biologically active, and possibly drug bearing system was proposed to replace
polymeric coating on stent as surface modification. This system comprises self-grown
nanoarchitectures for Ti-17Nb-6Ta alloy that has potential for use in fabricating self-expandable
stents.
Two nanotube (NTs) morphologies were successfully fabricated for the same substrate
using anodization technique: 1) Homo-NTs, characterized by highly ordered, vertically aligned
nanotubes of uniform and homogeneous tubes diameter, closely packed into islands separated by
grooves. 2) Hetero-NTs, characterized by highly ordered, vertically aligned nanotubes but of
non-uniform and heterogeneous tubes diameter, yet, evenly distributed along the substrate.
Different morphologies were obtained by using different types of electrolytes and conditions for
anodization setup.
XRD and Raman analysis for the as-anodized samples indicated the formation of the
anatase phase associated with annealed titania NTs. Possible overlapping of peaks from other
alloying elements (Nb and Ta), hindered accurate compositional analysis using those two
techniques. Therefore, XPS as more sensitive and highly powerful technique for elemental
analysis was used. It was able to confirm the formation of mixture oxides of the alloying
elements on the surface without totally losing one of the components during anodization.
Elemental analysis was further confirmed with EDX, which showed Ti, Nb, Ta and O with
overall composition relatively consistent with the composition of the substrate alloy.
Nanoindentation technique was used to obtain the Young’s modulus and hardness values
for the fabricated morphologies before and after annealing. It was reported that phase
transformation occurred with samples annealed resulted in higher values of Young’s modulus
and hardness for both samples. Comparative observation between the two morphologies revealed
that Homo-NTs showed the higher hardness, while Hetero-NTs gave higher stiffness values.
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For influence of the proposed system on endothelial healing, both morphologies (Homoand Hetero-NTs) were investigated in-vitro with cultured vascular endothelial cells. First,
cytotoxicity study was done to assess the material biocompatibility. By using, MTT assay it was
found that after incubation of samples’ extracts with cells for 48 hours, concentration of viable
cells were almost similar to cell control. Both morphologies as well as substrate material showed
no cytotoxicity and were ready for further biological investigation. For proliferation studies
Trypan blue cell count and MTT assay were undertaken for samples cultured with cells for 1, 3
and 7 days. Along the three time intervals, nanoarchitectures showed significantly better results
for endothelial cells proliferation. Furthermore, Homo-NTs showed superior activity than
Hetero-NTs for biological response.
Drug loading capacity was practically investigated and compared for the two
morphologies using 2’- Deoxyadenosine drug. Results were as well in favor of Homo-NTs,
which showed higher amount of drug retained from initially added concentration. The drug
release profile for this system was then simulated and calculated through computational studies
using COMSOL

®

Multiphysics software with transport of diluted species module. Within a

diffusion controlled physical model, a time dependent study calculated drug concentration
released from the NTs into the tissue across time. It reported that almost 100% of the practically
loaded amount would be eluted from the NTs within a duration of 3 days. Although this may be
considered relatively fast rate for the intended application, it is expected that by increasing
initially loaded amount, tuning tubes diameter and using hydrophobic drugs, more sustained
release can be obtained.
Finally, for future perspectives some complimentary work can be suggested as follow:
-

Further in-depth mechanical investigation of the NTs layer is required to ensure the
mechanical integrity of the system during PTCA and on the long term within the vessel.

-

Studying surface hydrophilicity, which may directly affect its interaction with blood
components and thrombus formation.

-

Effect of nanoarchitecture on VSMC proliferation that may influence restenosis.

-

Practical investigation of drug release kinetics to support computational calculations.

-

Investigating drug loading capacities and release profile with higher initial drug
concentrations and for hydrophobic drugs.
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